Integrated Health Services to Reduce Opi[INVESTIGATOR_467880]: The INSPI[INVESTIGATOR_467881]:  18-0703  
PI: [INVESTIGATOR_467882], PhD, MSPH  
National Clinical Trial (NCT) Identifie r Number: [STUDY_ID_REMOVED]  
Sponsor : RTI International  
Funded by:  [CONTACT_19045] -Centered Outcomes Research Institute (PCORI)  
Version Date:  03/30/2022  
Version number:  16 
 
CHANGE LOG*  
Version date  Version 
Number  Changes  
07/27/2018  0.1 Initial version submitted to UNC Scientific Review Committee  
08/01/2018  0.2 Version sent to PCORI.  
• Added cover page and IRB number  
• Wording revisions for clarity and to reduce redundancy  
09/06/[ADDRESS_599576] version submitted to UNC IRB.  
• Added contact [CONTACT_468091]  
• Added CBT as an exclusion  
• Added active suicidal ideation as exclusion  
• Added screening items to protocol  
• Added information about qualitative data component  
• Revised Efficacy Evaluation section and Statistical Analysis section to 
respond to SRC comments  
• Added revised SDM materials  
• Added safety protocol as an appendix and added references to protocol  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Front Matter  
Page 2 of 81 CHANGE LOG*  
Version date  Version 
Number  Changes  
10/30/2018  2.0 Version re -submitted to IRB to respond to sti pulations:  
• Added recruitment manual, recruitment  script, FAQ, voicemail/message 
script, screening and consent script, screening informed consent form, 
study informed consent form, HIPAA authorization form, SDM patient 
handouts, MI -CBT patient handouts, MI -CBT therapi[INVESTIGATOR_34712], T2/T3 
follow -up survey, alternate contact [CONTACT_468092], and DSMB charter as appendices 
and added references throughout the protocol  
• Clarified the study phase  
• Clarified the roles and responsibilities of the study team  
• Changed consent to scr een from verbal to written  
• Added DSMB description  
• Added rationale for interventions  
• Revised description of recruitment targets across sites  
• Added English language inclusion criterion  
• Clarified which exclusion criteria relate to past medical history  
• Revised description of policy regarding blanket permission to contact  
• Added rationale for excluding patients for other reasons at investigator’s 
discretion  
• Clarified factors that are not exclusion criteria  
• Added information about UDTs  
• Clarified recruitment  staff roles  
• Added recruitment plan information  
• Added measures to reduce coercion; removed language about emphasizing 
the importance of follow -up to patients  
• Added that total compensation is under $200  
• Changed extraction of EHR data from opt -out to opt -in consent if patient 
withdraws from study  
• Added expectations for qualitative data collection; removed incentive 
amount for qualitative activities  
• Added satisfaction with care as an outcome measure and removed 
knowledge check  
• Removed interim analysis  
• Added in formation about MI -CBT provider training/qualifications  
• Added potential for risk for opi[INVESTIGATOR_467885]  
11/29/2018  3.0 Version re -submitted to IRB to respond to stipulations:  
• Added information about study rationale to study overview and to 
introduction  
• Revised cancer -related exclusion criterion  
• Added information about the additional costs of participating in the study  
• Added Withdrawal Consent Addendum to seek permission to extract EHR 
data if patient withdraws from study  
• Clarified opi[INVESTIGATOR_467886] 1  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Front Matter  
Page 3 of 81 CHANGE LOG*  
Version date  Version 
Number  Changes  
12/06/[ADDRESS_599577] modification  
• Changed opi[INVESTIGATOR_467887] [ADDRESS_599578] on study sa mple size or 
power. We also made administrative updates to power calculations in the 
protocol  
• Added clarifications regarding the cost of the intervention  
• Revised the number of contact [CONTACT_14386]   
02/21/2019  5.0 Version submitted to IRB for study amendment:  
• Clarified inclusion criteria that patient must be on opi[INVESTIGATOR_197935] -
cancer pain (CNCP)  
• Added that we will confirm in the EHR that the actual dosage prescribed is 
at least 40 mg daily MED.  
• Clarified that patients taking opi[INVESTIGATOR_467888] (OUD) will be excluded from the study  
• Updated CONSORT diagram and Figure 5 to match the above clarifications  
• Clarified that lack of insurance is not an exclusion criterion   
• Added patient -centered communication measure to surveys  
• Added text messaging as a recruitment method  
• Changed length of MI session to 30 to 60 minu tes  
• Removed language about sites obtaining a Certificate of Confidentiality; RTI 
will request the Certificate.  
• Removed language about participants in CBT not being asked to share full 
names  
• Removed reference to using pain contract as a proxy for cognitiv e status  
• Participating clinicians will affirm relevant training but will not be required 
to produce documentation  
• Clarified the process evaluation plan  
• Fixed reference to CBT -MI providers to include licensed professional 
counselors and other licensed clinicians.  
• Minor administrative revisions to data management section  
• Added change log, revised cover page  
3/26/2019  6.0 • Removed text messaging as a recruitment method after receiving IRB 
guidance that text messaging is not allowable for recruitment purposes.  
07/03/2019  7.0 • Added brochure as a recruitment method.  
• Added patient incentive receipt.  
11/0 7/2019  8.0 • Updated the  T2/T3 follow -up survey protocol  
• Changed the upper age limit for exclusion criteria from 75 to 85 years  
• Removed  current CBT exclusion criterion  
• Clarifi ed cancer exclusion criterion  
• Update d the  name [CONTACT_468166] -South CDRN to STAR CRN  
• Updated the plans for data management for T2 and T3 follow -up surveys  
• Removed the exclusion criterion about visit scheduled within n ext 90 days. 
This criterion is not clinically meaningful.  
• Revised  the post -CBT group session form  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Front Matter  
Page 4 of 81 CHANGE LOG*  
Version date  Version 
Number  Changes  
12/13/2019  9.0 • Changed opi[INVESTIGATOR_467887] [ADDRESS_599579] on study sample size or 
power. We also made administrative updates to power calculations in the 
protocol.  
• Removed current CBT exclusion criterion as per PCORI request  
4/16/2020  10.0  • Describe d remote intervention delivery measures  
• Clarifi ed enrollment procedures for Arm 1  
07/08/2020  11 • Describe d remote enrollment procedures  
06/30/2021  12 • Decreased the target sample size from 1,060 to 608 . Updated power 
calculations .  
• Revised the study timeline and duration.  
• Described  qualitative research activities  for focus groups and individual 
interviews with enrolled participants,  
• Updated recruitment and retention procedures (removed contact[CONTACT_468093]; added option to contact [CONTACT_468094]; added option to send text mess age reminders to enrolled 
participant about follow -up surveys; added option to mail follow -up surveys 
to participants).  
• Updated study safety reporting procedures.  
• Updated background information about opi[INVESTIGATOR_467889] . 
• Made minor clarifications regarding remote enrollment and remote 
intervention delivery.   
08/09/2021  13 Revised to respond to IRB stipulations : 
• In section 3.6, removed collection of participant alternate information.  
• In section 3.9.2, replaced “Stakeholder Advisory Committee” with “SAC” 
which is a reference to the Study Advisory Committee as defined in the 
Abbreviations section.  
• In section 3.9.2, in reference to planned periodic newsletter, deleted “if 
required” which  followed “newsletter content will be submitted to IRB for 
approval.”  
Corrected minor errors:  
• Replaced reference to “section X” with “section 3.9.3” in Table 2 , reference 
to “Table 7” with “Table 9” in section 6.3.1; reference to “Table 8” with 
“Table 10” in section 7.2 , and reference to “Table 9” with “Table 11” in 
section 8.3.1.  
• Updated headers and footers in Sections 4 -12.  
10/07/[ADDRESS_599580] of attachments.  
12/23/2021  15 Revised to include publicly available data as a data source.  
 
3/30/2022  16 Revised to describe procedures related to requesting death certificates: maintaining 
the confidentiality of the data, procedures for ensuring the privacy of subjects, and 
how these data will be used.  
*Version numbers will be updated upon subsequent final versions submitted to IRB with additions, modifications, 
and deletions described .
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Front Matter  
Page 5 of 81 Principal Investigators  
Study Principal Investigator (PI)  
RTI International  
Lauren McCormack, PhD, MSPH  
[ADDRESS_599581], [PO_BOX]  
Research Triangle Park, NC [ZIP_CODE] -2194  [LOCATION_003] 
Phone: 919 -541-6277  
email: [EMAIL_8959]  
 
Duke University Institution  PI 
[CONTACT_85444]-Tzy Wu, RN, ScD, MA  
Duke South Hospi[INVESTIGATOR_307], Rm 3521, Box 3903  
Durham, NC [ZIP_CODE] [LOCATION_003]  
Phone: 919 -889-9369  
Email: [EMAIL_8960]  
 
University of North Carolina at Chapel Hill Institution  PI 
[INVESTIGATOR_467890], MD, MPH, FACP  
5034 Old Clinic Building, CB# 7110  
Chapel Hill, NC [ZIP_CODE] [LOCATION_003]  
Phone: 984 -974-4462  
Email: [EMAIL_8961]   
 
Vanderbilt University Institution  PI 
[INVESTIGATOR_467891], PhD, DPT  
[ADDRESS_599582]  
Nashville, TN [ZIP_CODE] [LOCATION_003]  
Phone: 615 -322-2732  
Email: [EMAIL_8962]   
  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599583] or Intervention  ................................ .........  17 
1.3 Nonclinical and Clinical Study Findings  ................................ ................................ ...................  19 
2 Study Objectives and Design  ................................ ................................ ................................ .............  22 
2.1 Primary Objective  ................................ ................................ ................................ ....................  22 
2.2 Secondary Objectives  ................................ ................................ ................................ ..............  22 
2.3 Study Design  ................................ ................................ ................................ ............................  22 
2.4 Random Allocat ion to Treatment Groups and Blinding  ................................ ..........................  22 
2.5 Study Duration ................................ ................................ ................................ .........................  24 
2.6 Study Enrollment and Number of Subjects  ................................ ................................ .............  24 
2.7 Study Population  ................................ ................................ ................................ .....................  24 
2.8 Inclusion and Exclusion Criteria  ................................ ................................ ...............................  25 
3 Study Procedures  ................................ ................................ ................................ ..............................  28 
3.1 Identification of Potential Participants  ................................ ................................ ...................  29 
3.2 Eligibility Screening  ................................ ................................ ................................ ..................  31 
3.3 Recruitment  ................................ ................................ ................................ .............................  31 
3.4 Screening  ................................ ................................ ................................ ................................ . 35 
3.5 Informed Consent  ................................ ................................ ................................ ....................  36 
3.6 Enrollment and Baseline Data Collection  ................................ ................................ ................  37 
3.7 Screen Failures  ................................ ................................ ................................ ........................  38 
3.8 Randomization and Intervention Delivery  ................................ ................................ ..............  38 
3.9 Follow -up Assessment Procedures ................................ ................................ ..........................  38 
3.10  Incentives for Study Participation  ................................ ................................ ...........................  41 
3.11  Study Completion  ................................ ................................ ................................ ....................  42 
3.12  Withdrawal from the Study  ................................ ................................ ................................ ..... 42 
3.13  Loss to Follow -up ................................ ................................ ................................ .....................  42 
4 Study Evaluations and Measurements  ................................ ................................ ..............................  43 
4.1 Efficacy Evaluation  ................................ ................................ ................................ ...................  43 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Front Matter  
Page 7 of 81 4.1.1  Primary Outcome  ................................ ................................ ................................ ....................  43 
4.1.2  Secondary Outcomes  ................................ ................................ ................................ ..............  43 
4.1.3  Other Self -Reported Outcomes  ................................ ................................ ...............................  44 
4.1.4  Other EHR -Derived Outcomes  ................................ ................................ ................................ . 45 
4.2 Safety Evaluations  ................................ ................................ ................................ ...................  46 
4.3 Process Evaluation  ................................ ................................ ................................ ...................  46 
5 STATISTICAL CONSIDERATIONS  ................................ ................................ ................................ .........  48 
5.1 Summary of Statistical Analysis  ................................ ................................ ...............................  48 
5.2 Study Endpoints  ................................ ................................ ................................ .......................  49 
5.3 Statistical Analysis Methods  ................................ ................................ ................................ .... 50 
5.4 Sample Size and Power  ................................ ................................ ................................ ...........  53 
5.5 Interim Analysis  ................................ ................................ ................................ .......................  55 
6 Study Intervention  ................................ ................................ ................................ ............................  56 
6.1 Guideline Concordant Care Intervention  ................................ ................................ ................  56 
6.2 SDM  Intervention  ................................ ................................ ................................ ....................  57 
6.3 MI+CBT -CP Intervention  ................................ ................................ ................................ ..........  59 
7 Study Intervention Training and Documentation  ................................ ................................ .............  62 
7.1 CDC Guidelines Training Material Content for Providers  ................................ ........................  62 
7.2 SDM Provider Training ................................ ................................ ................................ .............  62 
7.3 MI+CBT -CP Provider Training  ................................ ................................ ................................ .. 62 
7.4 Research Coordinator Training  ................................ ................................ ................................  62 
8 Safety Management  ................................ ................................ ................................ ..........................  63 
8.1 Potential for Risk  ................................ ................................ ................................ .....................  63 
8.2 Risk Monitoring  ................................ ................................ ................................ .......................  65 
8.3 Adverse Event/Serious Adverse Event monitoring and reporting procedures  .......................  65 
9 Data Management  ................................ ................................ ................................ ............................  69 
9.1 Pre-Enrollment Data Management  ................................ ................................ .........................  69 
9.2 Enrolled Participant Data Management  ................................ ................................ ..................  69 
9.3 Follow -Up Survey Data Management  ................................ ................................ .....................  70 
9.4 Qualitative Data Management  ................................ ................................ ................................  70 
9.5 Quality Assurance  ................................ ................................ ................................ ....................  70 
10 Confidentiality of the Data  ................................ ................................ ................................ ................  71 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599584] of Tables   
Table  1. Pre -enrollment Study Phases, Procedures, and Materials  ................................ ............................  28 
Table  2. Study Phases, Procedures, and Materials for Enrolled Participants  ................................ .............  29 
Table  3. Primary and Secondary Outcomes  ................................ ................................ ................................  44 
Table  4. Additional Self -Reported Outcome Measures  ................................ ................................ ..............  45 
Table 5. Process Evaluation ................................ ................................ ................................ .........................  46 
Table 6. Schedule of Assessments  ................................ ................................ ................................ ..............  47 
Table 7. Sample Size Required to Obtain 80% Power for Primary and Key Secondary Outcomes  ............  55 
Table 8. Power for Primary and Key Secondary Outcomes with N=[ADDRESS_599585] of Figures  
Figure  1. Study Design  ................................ ................................ ................................ ................................ . 22 
Figure  2. CONSORT 2010 Flow Diagram Shell  ................................ ................................ .............................  23 
Figure  3. Study Timeline ................................ ................................ ................................ ..............................  24 
Figure  4. Study Phases Flow Diagram  ................................ ................................ ................................ .........  28 
Figure 5. Recruitment Diagram  ................................ ................................ ................................ ...................  33 
 
  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Front Matter  
Page 9 of 81 Appendix ( List of Attachments ) 
A. Consent Forms  
Document Type  File Name  
[CONTACT_468167]  • INSPI[INVESTIGATOR_467892]_2019 -02-21.docx  
• INSPI[INVESTIGATOR_467893] 2019 -11-05.docx  
• INSPI[INVESTIGATOR_467894] - clean.docx  
Consent addendum for 
current subjects  • INSPI[INVESTIGATOR_467895].docx  
• INSPI[INVESTIGATOR_467896] 2019 -11-05.docx  
• INSPI[INVESTIGATOR_467895] -VUMC - Tracked.docx  
HIPAA Authorization  • INSPI[INVESTIGATOR_467897]_ 2021 -12-23.docx  
• INSPI[INVESTIGATOR_467898]_2018 -12-[ADDRESS_599586] Injury and HIPAA Included 
- Clean_final.docx  
Other Consent Materials  • INSPI[INVESTIGATOR_467899]_2019 -02-12.docx  
• INSPI[INVESTIGATOR_467899]_Duke_2019 -11-05.docx  
• INSPI[INVESTIGATOR_467900]_2019 -06-12.docx  
• INSPI[INVESTIGATOR_467901] 2021 -06-28.docx  
• INSPI[INVESTIGATOR_467902] 2021 -08-09.docx  
 
B. Other Attachments  
Document Type  File Name  
[CONTACT_468168]  • INSPI[INVESTIGATOR_467903] v16 2022-03-30 
Other Study Protocol  • INSPI[INVESTIGATOR_467904]+CBT Patient Packet_FINAL_2020 -06-25.pdf  
• INSPI[INVESTIGATOR_467905]_2020 -04-16.pdf  
• INSPI[INVESTIGATOR_467906] v3 2020 -07-08.docx  
• MI and CBT for Chronic Pain Manual v4 2020 -06-24.docx  
DSMB Charter or 
Stoppi[INVESTIGATOR_1869]  • INSPI[INVESTIGATOR_21392] B4 DSMB Charter V4 2020 -final version_signed.pdf  
DSMB/DSMC Report  • DSMB Recommendation letter_for signature_2020 -11-17--signed by [INVESTIGATOR_231215] 11 -29-
20.pdf  
• INSPI[INVESTIGATOR_467907](2019.09.17)_OPEN_Final.pdf  
• INSPI[INVESTIGATOR_467907]_Open_FINAL_2021 -07-16.pdf  
• DSMB Recommendation letter_for signature_2021 -08-03 signed 2021 -08-06.pdf  
Email or Listserv 
Recruitment  • INSPI[INVESTIGATOR_467908] 2020 -07-08.docx  
• INSPI[INVESTIGATOR_467909] 2020 -07-10.docx  
Recruitment Listing PDF – 
Research for Me @ UNC  • RFM_ResearchStudy_18 -0703_2020 -07-16_1527_to submit with 
modification_Reviewed by [CONTACT_468095]_1.pdf  
Recruitment Follow -Up • INSPI[INVESTIGATOR_467910] 2021 -06-25.docx  
• INSPI[INVESTIGATOR_21392] T1 Emails 2020 -07-10.docx  
Script for In -Person 
Recruitment  • INSPI[INVESTIGATOR_467911] 2020 -07-14.docx  
Flyer for Recruitment  • 13343_INSPI[INVESTIGATOR_467912]_D[LOCATION_006]E_Printer.pdf  
• 13343_INSPI[INVESTIGATOR_467912]_UNC_v2.pdf  
• 13343_INSPI[INVESTIGATOR_467912]_v3.pdf  
• 13343_INSPI[INVESTIGATOR_467912]_VUMC_v2.pdf  
• INSPI[INVESTIGATOR_467913] 2018 -11-28.docx  
Letter for Recruitment  • INSPI[INVESTIGATOR_467914] v2 2020 -07-05.docx  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Front Matter  
Page 10 of 81 Document Type  File Name  
[CONTACT_468169]  • INSPI[INVESTIGATOR_467915]_2019 -06-25.doc  
• INSPI[INVESTIGATOR_467916] 2019 -05-22.pdf  
• INSPI[INVESTIGATOR_467917] 2020 -07-08.docx  
• INSPI[INVESTIGATOR_467918] v5 2020 -07-09.docx  
• INSPI[INVESTIGATOR_467919] 2020 -07-10.docx  
• Summary_Sheet_UNC.pdf  
Telephone Script for 
Recruitment  • INSPI[INVESTIGATOR_467920]_2019 -03-26_final.docx  
• INSPI[INVESTIGATOR_467921]_2019 -05-22.docx  
Electronic Questionnaire 
Survey  • INSPI[INVESTIGATOR_21392] T1 Baseline Survey_2019_02 -21.docx  
Interview Questionnaire 
Survey  • INSPI[INVESTIGATOR_467922] 2021 -06-28.docx  
• INSPI[INVESTIGATOR_467923] 2021 -08-09.docx  
Other Questionnaire 
Survey  • INSPI[INVESTIGATOR_21392] T2 and T3 Follow -Up Survey_2019 -10-21.docx  
Certificate of 
confidentiality  • 18-0703 Chelminski CoC Assurance Page ex'd 4 -1-19.pdf  
Data Use Agreement  • [ZIP_CODE] DUA FE.pdf  
• Data Use Agreement for Carolina Data Warehouse (Patient Authorization or IRB 
Waiver) (00056536 -6)_Version2.0 _06282019 -FullyExecuted.pdf  
Scientific Review 
Committee Approval 
Letter  • 18-SRC057_Chelminski_IRB Documents_(2018 -07-30).pdf  
Other  • INSPI[INVESTIGATOR_467924] 2020 -07-08.docx  
• Figure 1_Recruitment Process Flowchart.pdf  
• INSPI[INVESTIGATOR_467925] 2021 -06-28.docx  
• INSPI[INVESTIGATOR_467926] 2021 -06-28.docx  
• INSPI[INVESTIGATOR_467927] 2021 -10-07.docx  
Scientific R eview 
Documentation  • 18-SRC057_Chelminski_SRC review_clean_compi[INVESTIGATOR_344]_(2018 -07-26).pdf  
 
Abbreviations  
Abbreviation  Definition  
AE adverse event  
AHRQ  Agency for Healthcare Research and Quality  
CBT-CP Cognitive Behavioral Therapy for Chronic Pain  
GCC  guideline -concordant care  
CATI  Computer -Assisted Telephone Interviewing  
CDC Centers for Disease Control and Prevention  
CDM  common data model  
CFR Code of Federal Regulations  
CI confidence interval  
CITI Collaborative Institutional Training Initiative  
CME  Continuing Medical Education  
CNCP  chronic noncancer pain  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599587]  
ICD-9 International Classification of Diseases, 9th Revision  
ICD-10 International Cla ssification of Diseases, 10th Revision  
INSPI[INVESTIGATOR_467928]: Interventions to Reduce pain Effectively  
IOM  Institute of Medicine  
IRB Institutional Review Board  
ITT intent to treat  
LTF loss to follow -up 
MAR  missing at random  
MCID  minimal clinically important differences  
MED  morphine -equivalent dose  
MI motivational interviewing  
MID  minimally important difference  
NCT National Clinical Trials  
NIH National Institutes of Health  
NPS National Pain Strategy  
OHRP  Office for Human Research Protection  
OUD  Opi[INVESTIGATOR_467929] -Centered Outcomes Research Institute  
PCORNet  National Patient -Centered Clinical Research Network  
PCP  primary care provider  
PDMP  Prescription Drug Monitoring Program  
PHI Protected Health Information  
PI [INVESTIGATOR_467930] -Reported Outcomes Measurement Information System  
PROMIS -PF Patient -Reported Outcomes Measurement Information System —Physical Functioning  
PROMIS -PI [CONTACT_19045] -Reported Outcomes Measurement Information System —Pain Interference  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599588] deviation  
SDM  Shared De cision Making  
SFTP  Secure File Transfer Protocol  
STAR CRN  Stakeholders, Technology and Research Clinical Research Network  
SUD  substance use disorder  
UNC  University of North Carolina  
UDT  urine drug testing  
VUMC  Vanderbilt University Medical Center  
 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Protocol Synopsis  
Page 13 of 81 Protocol Synopsis  
PROTOCOL SYNOPSIS  
Title Integrated Health Services to Reduce Opi[INVESTIGATOR_467931]  
(Short title: Integrated Services for Pain: Interventions to Reduce pain Effectively 
(INSPI[INVESTIGATOR_21392]))  
Clinical Phase  The research is a pragmatic trial and does not fit within the usual framework of the 
clinical trial rubric of phase I -IV phases  
Study Team  RTI International (RTI) was awarded funding from the Patient -Centered Outcomes 
Research Institute (PCORI) and is the data coordinating center. To the extent 
permitted under applicable law, RTI has full responsibility and liability for the conduct 
of the study and for the results reported. Three sites will be enrolling participants for 
the INSPI[INVESTIGATOR_208847]:  
• Duke University  
• The University of North Carolina at Chapel Hill  (UNC)  
• Vanderbilt University  Medi cal Center (VUMC)  
Study Rationale  • Up to one -third of Americans suffer from chronic noncancer pain (CNCP).  
• Opi[INVESTIGATOR_467932]. Once on chronic opi[INVESTIGATOR_2538] (COT), 
individuals often continue  with this class of medication for years.  
• Evidence for the effectiveness of COT to treat CNCP is limited, exposing 
individuals to known risks.  
• Modified  or novel pharmacological and nonpharmacological  strategies are 
needed to  improve pain management  and promote informed decision making  
regarding possible opi[INVESTIGATOR_46217] . 
• This project will evaluate two nonpharmacologic approaches to pain management 
and opi[INVESTIGATOR_467933].  
• The appro aches are designed to educate  medical care providers and patients  
currently being treated for CNCP , help patients address pain and pain copi[INVESTIGATOR_25146] , and enhance patient motivation to reduce or discontinue opi[INVESTIGATOR_2441]   
• This study will determine the feasibi lity, effectiveness,  and potential scalability of 
these interventions in reducing opi[INVESTIGATOR_467934] 20 
morphine equivalent doses [MED]).  
• The study will also assess patient acceptability of the interventions including 
involvement in their implementation and willingness to incur out -of-pocket costs 
associated with the visits.  
Objective  To conduct a multisite pragmatic trial of two active interventions : shared decision 
making (SDM) as compared with cognitive behavioral t herapy for chronic pain with 
motivational interviewing (MI+CBT -CP). 
Primary Objective  
• To assess if the intervention s result in opi[INVESTIGATOR_467935] . 
Secondary  Objectives  
• To examine the impact of the interventions on physical function.  
• To examine the impact of the interventions on pain interference .  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Protocol Synopsis  
Page 14 of 81 PROTOCOL SYNOPSIS  
Description of Study 
Intervention  Intervention 1 (Arm 1)  
• The Shared Decision -Making  intervention is patient -provider communication 
intervention to explor e and compare treatment options for chronic pain , assess a 
patient’s values and preferences, and reach a shared decision about chronic pain 
treatment . 
• Patients randomized to Arm [ADDRESS_599589] their study visits and opi[INVESTIGATOR_467936] -trained provid er at their practice.  
Intervention 2  (Arm 2)  
• The Motivational Interviewing Plus Cognitive Behavioral Therapy (CBT) for 
Chronic Pain intervention is an empi[INVESTIGATOR_467937]-CP, and the use of CBT -CP to enhanc e pain copi[INVESTIGATOR_25110].  
• One individual MI session that will focus on patient engagement and enhancing a 
patient’s own intrinsic motivation for CBT -CP participation. MI will also be woven  
into the group CBT-CP sessions.  
Participants in each study arm will receive guideline -concord ant pharmacotherapy 
treatment, based on clinical guidelines for opi[INVESTIGATOR_467938].  
Study Design  This study is a multisite, randomized pragmatic trial to examine the comparative 
effectiveness of 2 interventions : 
1. A guideline -concordant pharmacotherapy  approach with SDM (Arm 1)  
2. A guideline -concordant pharmacotherapy approach with  CBT-CP and MI (Arm 2)  
Subject Population  
Key Criteria for Inclusion 
and Exclusion  Inclusion Criteria  
• Ages 18 to 85 years  
• History of CNCP  
• Average daily dose of at least 20 mg morphine -equivalent dose (MED) for CNCP 
according to most recent prescription  
• Receiving care at a participating clinic from a participating provider as evidenced 
by a t least [ADDRESS_599590] 12 months  
Exclusion Criteria  
• Opi[INVESTIGATOR_467939] a cancer diagnosis  
• Opi[INVESTIGATOR_467940] (OUD)  
• Suicide attempt within the past 3 years  
• Active suicidal ideation  
• Currently receiving CBT  
• Non -English speaking  
• Other reason at the discretion of the investigator  
Number of Subjects  [ADDRESS_599591] 72 months, from February 2018 to January 2024.  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Protocol Synopsis  
Page 15 of 81 PROTOCOL SYNOPSIS  
Study Phases  
Prescreening  
Screening  
Enrollment  
Randomization  
Intervention  
Follow -up  Prescreening:  Potentially eligible participants will be identified through electronic 
health records (EHRs) and invited to participate.  
Screening:  The Research Coordinator will explain the study to the potential 
participant . Potential participants  will provide written or electronic consent  to 
complete screening . The Research C oordinator will screen the participant.  
Enrollment:  Eligible participants will be asked to provide written or electronic consent  
to take part in the study  and written  or electronic HIPAA authorization . Once 
consented, they will take a baseline survey to complete enrollment.  
Randomization/Allocation:  Once enrolled, participants will be randomized  to either 
Arm 1 or Arm 2 of the inter vention  using a 1:1 ratio .  
Intervention: In Arm 1, participants and provider s will engage in SDM.  In Arm 2, 
participants will attend  MI+CBT -CP sessions . Participants in both  study arm s will 
receive guideline -concordant pharmacotherapy treatment, based on Center for 
Disease Control and Prevention (CDC) clinical guidelines for COT for CNCP.  
Follow -up: A comprehensive, multimode data collection method will be used that 
includes collecti ng patient -reported outcomes through Web -based and telephone 
approaches and leverag ing existing harmonized EHR data maintained by [CONTACT_468096] . Considering the pragmatic nature of the trial, w e will track loss  to follow -
up (LTF) and intervention  fidel ity. 
Efficacy Evaluations  • The primary outcome, opi[INVESTIGATOR_467941], will be assessed using 
prescribing information from the EHRs . This outcome will be assessed at 6, 12, and 
18 months after enrollment.  
• Patient self -reported outcomes, including physical function and pain interference, 
will be measured via patient survey at 3 timepoints: baseline, [ADDRESS_599592] (DSMB) w ill monitor for 
potential adverse events (AEs) and serious adverse events (SAEs).  This DSMB consists 
of three individuals who are not participating investigators in this trial, who were 
nominated by [CONTACT_468097], and appointed by  [CONTACT_30292], RTI. The board includes a primary care clinician, a psychiatry researcher, and 
a biostatistician.  
Statistical and Analytic 
Plan Clinical  and patient -reported outcomes  will be evaluated  using cross -sectional and 
longitudinal intent -to-treat analyses. These analyses will use mixed effects models to 
compare opi[INVESTIGATOR_467942] [ADDRESS_599593] according to participant 
characteristics, such as age, sex, baseline pain level, baseline opi[INVESTIGATOR_40533], and the 
presence of physical comorbidities, mental health comorbidities, or a history of 
substance misuse or abuse . 
Data and Safety 
Monitoring Plan  
(Cross -reference: UNC IRBIS 
application section 1.7.1)   The study PI [INVESTIGATOR_467943] . They will be aided by [CONTACT_66633] ( DSMB ), which will rev iew cumulative study data to evaluate 
intervention safety, study conduct, scientific validity, and data integrity to ensure that 
the study is operating in a safe and ethical manner .  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Background and Rationale  
Page 16 of 81 1 BACKGROUND AND RATIONALE  
Cross -reference : UNC IRBIS Application section A.1.1.  
1.1 Introduction  
Chronic noncancer pain (CNCP) is common, and the societal and clinical burden is high. A recent 
Institute of Medicine (IOM) report estimated that up to one -third of Americans suffer from CNCP.1,2 
With current treatment approaches, 13% of headache patients and 18% of back pain patients remain 
unable to work full time because of pain.3 CNCP costs the [LOCATION_002] up to $[ADDRESS_599594] for cancer or diabetes or heart disease.4 The etiology of a patient’s CNCP is often 
poorly understood, and no physiological test can objectively identify its presence or intens ity. Mental 
health disorders and substance use disorders (SUDs) are often comorbid with CNCP.5-[ADDRESS_599595] relied disproportionately on pharmacologic approaches, 
typi[INVESTIGATOR_467501], to treat pain. Prescribed opi[INVESTIGATOR_467944] 1990s and 2000s, 
peaking around 2011, 11-18 and has decreased 60% since that time.18 (However, due to data lags, this 
peak did not become apparent until around 2015).  Whereas 50% of all the prescriptions written by [CONTACT_468098][INVESTIGATOR_2438], only 6% of the prescriptions written by [CONTACT_200791] (PCPs ) are for 
opi[INVESTIGATOR_2438]. However, PCPs  write 56% of all opi[INVESTIGATOR_75155].[ADDRESS_599596] prescription opi[INVESTIGATOR_467945] (COT) for CNCP . Patients initiating COT remain on this treatment for years . 20,[ADDRESS_599597] likely 
to discontinue COT.  
Despi[INVESTIGATOR_467946], opi[INVESTIGATOR_307533] a challenging treatment modality for CNCP. Their 
efficacy is incomplete,  and some individuals may receive little or no pain relief from COT. A recent 
Agency for Healthcare Research and Quality (AHRQ) systematic review concluded tha t evidence for the 
effectiveness of COT is insufficient.[ADDRESS_599598] evaluated the effects of discontinuing opi[INVESTIGATOR_467947], function, quality of life, or 
withdrawal symptoms. Despi[INVESTIGATOR_467948], it is 
commonly used in practice.  
Further, COT has substantial potential for harm. Opi[INVESTIGATOR_467949] 
“epi[INVESTIGATOR_901],”16,[ADDRESS_599599] of opi[INVESTIGATOR_467950] $55.7 billion 
in 2007.25 In younger persons, new marijuana use and new misuse of prescription opi[INVESTIGATOR_467951].26,27 Other substantial unintended consequences include opi[INVESTIGATOR_2480] -induced decrease s in quality 
of life. The Centers for Disease Control and Prevention (CDC), the Federation of State Medical Boards, 
and individual state medical boards have issued guidelines to promote the safe and effective prescribing 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Background and Rationale  
Page 17 of 81 of opi[INVESTIGATOR_2467]. These guideli nes advise that opi[INVESTIGATOR_467952]. Clinical guidelines for opi[INVESTIGATOR_467953], monitoring, and reducing opi[INVESTIGATOR_467954]. 
However, the guidelines and scientific literature generally provide only limited discussion of opi[INVESTIGATOR_467955] -based approach is not working for the patient. That is, 
guidelines address only the technical asp ects of reducing medication dosages for COT (i.e., how quickly 
to decrease the dosage ).28-32 Importantly, the existing literature does not discuss how to motivate 
individuals to discontinue or decrease their opi[INVESTIGATOR_467956] ;[ADDRESS_599600]. The study will include opi[INVESTIGATOR_467957]. 
Individuals living in the Southeastern [LOCATION_002] (especially in rural Appalachia), younger persons, 
and individua ls with mental health disorders are at particularly high risk of serious opi[INVESTIGATOR_467958]. Appalachian areas have very high rates of opi[INVESTIGATOR_2441]. For example, using data from IMS Health, 
which collects a variety of healthcare information and is the la rgest vendor of U.S. physician prescribing 
data , McDonald and colleagues reported that Tennessee was 55% over and North Carolina was 18% 
over the national per -capi[INVESTIGATOR_467959].[ADDRESS_599601] dose of opi[INVESTIGATOR_467960] e non -opi[INVESTIGATOR_218947]. Often, 
physicians are not referring patients to cognitive behavioral therapy (CBT) as a non -opi[INVESTIGATOR_2538] —
partly because this is a challenge to do within a primary care setting and partly because patients are 
unaware that this is a  useful modality for pain management. Shared decision -making may also be a 
useful modality for managing opi[INVESTIGATOR_467961].  
This study will provide evidence on a key decisional dilemma facing prescribing opi[INVESTIGATOR_467962]: 
What is th e best way to facilitate opi[INVESTIGATOR_467963]/or who are interested in dose reduction?  The study takes a 
biopsychosocial approach to addressing pain, as outlined in t he National Pain Strategy (NPS).36 
Combining evidence -based behavioral interventions with pharmacological pain management is 
consistent with the NPS developed by [CONTACT_468099],36 and 
recommendations from a recent National Institutes of Health (NIH) panel.37 The NPS endorsed a 
“biopsychosocial model that is grounded in scientific evidence, integrated, multimodal, and 
interdisciplinary while at the patient level is tailored to individual needs.”36 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Background and Rationale  
Page 18 of 81 The study will examine the comparative effectiveness of two interventions for  treating chronic pain  
patients in a multisite, pragmatic trial. In Arm 1, patients and provider s will engage in Shared Decision 
Making (SDM) along with guideline concordant opi[INVESTIGATOR_243964]. In Arm 2, patients will 
participate in Motivational Interviewing Plus Cognitive Behavioral Therapy for Chronic Pain (MI+CBT -CP), 
along with receiving guideline concordant pharmacotherapy.  
1.2.1 Shared Decision Making  
SDM is a process in which provider s and patients work together to make decisions about tests and 
treatments by [CONTACT_468100], balancing the risks and expected outcomes, and 
respecting patient preferences and values.38 SDM  is an essential component of patient -centered health 
care39 and is critical for improving the quality of health care.  
Providers and patients often need to make decisions about te sts to be done or treatments to initiate, 
but the optimal decision for a patient can only be made if the patient is appropriately informed about 
the expected benefits, risks, and potential harms of all available options. This is particularly relevant 
when patients are at risk of negative outcomes from continued opi[INVESTIGATOR_2441], such as hyperalgesia and 
addiction, but are unaware that alternative options such as CBT, exercise, or mindfulness (e.g., 
meditation) may be beneficial. Studies have demonstrated the bene fit of SDM in improving patient -
centered outcomes for chronic illnesses such as diabetes, depression, and cardiovascular disease.[ADDRESS_599602] been found to improve know ledge of treatment options, help patients 
feel better informed, promote more accurate expectations of benefits and harms, and increase 
participation in decision making.41 SDM promotes a reciprocal rather than directive approach to care.  
RTI International, in collaboration with the University of North Carolina at Chapel Hill (UNC), recently 
completed an assessment and analysis of the “state of the science” on SDM and practice improvement 
in clinical encounters for AHRQ.[ADDRESS_599603], SDM was defined as “a health care provider and a 
patient working together to make a health care decision that is best for the patient. The optimal 
decision takes into account evidence -based information about available health care options, the 
provider's knowledge and experience, and the patient's values and preferences.”[ADDRESS_599604]. McCormack that RTI conducted for AHRQ to develop decision support tools for 
patients and conversational aids for providers to promote shared d ecision making in clinical settings.44 
1.2.2 Motivational Interviewing Plus Cognitive Behavioral Therapy for Chronic Pain  
The MI+CBT -CP behavioral approach has a broad evidence base.45 MI is an evidence -based, focused, 
goal -oriented counseling technique used to enhance an individual’s own intrinsic motivation for 
behavioral change.[ADDRESS_599605] guidelines refer explicitly to both MI and SDM 
as promising  modalit ies for effective patient engagement:29 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599606] appropriate 
action depends on the patient’s preferences. Many clinical consultations may require 
elements of both approaches, however. Both motivational interviewing and shared 
decision making are patient -cente red methods that promote the ethical imperative of 
respecting autonomy, and both have been associated with improved patient 
outcomes.”49, p. 270 
Recently, MI also has been used to help patients engage in CBT -CP. MI involves four processes: 
engaging, focusing, evoking, and planning. However, MI is not a protocol, but rather a way of talking and 
conversing with patients. Importantly, MI can be combined with psychotherapy, such as CBT -CP. We will 
use MI to enhance motivation both for (1) the CBT -CP intervention in general, to work toward goals of 
improved functioning, and (2) for opi[INVESTIGATOR_467964]. We believe this approach offers the 
greatest likelihood of decreasing reliance on opi[INVESTIGATOR_2438].  
CBT is an eviden ce-based psychotherapy used for an array of behavioral health and physical health 
conditions —including depression, for which it was initially developed, and for anxiety, insomnia, and 
chronic pain, such as lower back pain.50-[ADDRESS_599607] the negat ive thought, “nothing can be done to help 
my pain,” a type of thought that is known as “catastrophizing” that can lead to negative emotions such 
as depression and anger. Depression can worsen pain perception and make pain more difficult to treat. 
Further, depression can affect behaviors. For example, a depressed person may be less likely to engage 
in activities that might decrease the pain, such as moderate exercise, or pleasurable activities that might 
improve mood. This, in turn, can reinforce the pain cy cle. 
1.3 Nonclinical and Clinical Study Findings  
Cross -reference : UNC IRBIS Application section A.5.1.  
While multimodal approaches for treating pain are recommended, the evidence base for such 
interventions is relatively small, because in general pharmacotherapy and psychotherapy approaches 
have been tested in isolation. Further, little is known about the e ffects of multimodal approaches on 
opi[INVESTIGATOR_40533] , and whether individuals receiving multimodal approaches might require lower opi[INVESTIGATOR_467965]. Perhaps for this reason, the NPS stated that “research and demonstration efforts are needed that 
build on current know ledge, develop new knowledge, and support further testing and diffusion of model 
delivery systems.”36 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599608] been successful in a large -scale study at reducing opi[INVESTIGATOR_467966] -term while adequately managing pain symptoms. Although little has been p ublished on opi[INVESTIGATOR_187471], in a small study, Veterans (n=50) selected for opi[INVESTIGATOR_467967] a mean of 46% over 12 months, with 67% of these patients experiencing either no 
change in pain or reduced pain.63 In a more recent study,64 patients (N = 35) receiving COT for CNCP and 
interested in tapering their opi[INVESTIGATOR_467968] a 22 -week tap er support 
intervention (psychiatric consultation, opi[INVESTIGATOR_467969], and 18 weekly meetings with a physician 
assistant to explore motivation for tapering and learn pain self -management skills) or usual care. At [ADDRESS_599609] week (primary outcome) was lower in the taper support 
group; however, this difference was not statistically significant (adjusted mean difference = -42.9 mg; 
95% confidence interval [CI], -92.42 to 6.62; p = .09). Pain severity ratings (0 to 10 numeri c rating scale) 
decreased in both groups at 22 weeks, with no significant difference between groups (adjusted mean 
difference = -0.68; 95% CI, -2.01 to .64; p = .30). The taper support group improved significantly more 
than the usual care group in self -reported pain interference, pain self -efficacy, and prescription opi[INVESTIGATOR_467970] (all p -values < .05). This demonstrates that a support ed opi[INVESTIGATOR_467971], such as 
we are proposing  for this study , is feasible and shows promise in reducing opi[INVESTIGATOR_467972] . 
This research has the potential for high public health impact because the public health burden of high -
dose COT is significant, and the societal harm associated  with the epi[INVESTIGATOR_467973]. The significance of the study lies in the interventions, which are patient -centered, designed to 
be ea sily implemented and adopted in clinical practice, and have the potential for high public health 
impact. The MI+CBT -CP and SDM interventions do not require extensive training and are relatively 
straightforward to implement within existing care models. Both  interventions are economically feasible 
because provider s will be able to bill private insurers, Medicaid, and Medicare for the treatment. The 
CBT-CP portion, and some of MI, of the MI+CBT -CP intervention is delivered in a group setting, making 
the treatm ent more affordable. Perhaps more important is the fact that the group design allows more 
CNCP patients to receive the intervention, especially in underserved areas. A dditionally, the MI+CBT -CP 
intervention can be delivered by [CONTACT_193560], such as Masters - or PhD -level psychologists, licensed 
clinical social workers, or licensed professional counselors , and can be delivered in -person, or via 
telehealth.  
This real world, translational study will provide important evidence for health policymakers . While the 
interventions are evidence -based for pain management, the evidence for using these interventions for 
reducing opi[INVESTIGATOR_467974] -term studies and thus, adoption of the 
interventions is not widespread . If this study shows the  interventions are effective in a large -scale study 
and patients are willing to incur modest costs, this provides important data for influencing future 
coverage deci sions and policy -level change.  
Opi[INVESTIGATOR_467975] ; however, p articipants will be  free to choose whether 
they want to maintain their current opi[INVESTIGATOR_40533], decrease their opi[INVESTIGATOR_40533], or discontinue opi[INVESTIGATOR_467976]. Moreover, we anticipate that our intervention will simultaneously improve outcomes across 
several domain s: somatic pain, functioning, psychological well -being, and quality of life. The study will 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599610] a better 
understanding of the limitations of  the science regarding opi[INVESTIGATOR_2438].  Finall y, this study will also provide 
information on each intervention’s feasibility, effectiveness,  and potential scalability in reducing opi[INVESTIGATOR_467977] (at least 20 morphine equivalent doses [MED]). Beyond 
evaluating whi ch intervention is best for reducing opi[INVESTIGATOR_375324], the study will assess patient  
acceptability of the interventions including involvement in their implementation and willingness to incur 
out-of-pocket costs associated with the visits.  
 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Study Objectives  and Design  
Page 22 of 81 2 STUDY OBJECTIVES  AND DESIGN  
Cross -reference: UNC IRBIS Application section A.1.2  (objectives), A.4.2 (study design) , B.3.4 (setting)  
This study will compare the effectiveness of two interventions on potential opi[INVESTIGATOR_46217], 
functioning and pain interference. The study will be conducted in primary care and specialty pain clinics 
at 3 university hospi[INVESTIGATOR_600], 2 in North Carolina —The University of North Carolina at Chapel Hill (UNC) and 
Duke University, and 1 in Tennessee —Vanderbilt University Medical Center (VUMC).  RTI was awarded 
funding from PCORI and is t he data coordinating center for this study.  
2.[ADDRESS_599611] whether CNCP patients who receive guideline -concordant pharmacotherapy with a MI+CBT -CP 
intervention (Arm 2) have greater  opi[INVESTIGATOR_467978] -concordant pharmacotherapy integrated with SDM (Arm 1).  
2.[ADDRESS_599612] whether CNCP patients who receive guideline -concordant pharmacotherapy with an MI+CBT -CP 
intervention (Arm 2) have improved physical functioning  relative to the ir counterparts who receive 
guideline -concordant pharmacotherapy integrated with SDM (Arm 1).  
To test whether CNCP patients who receive guideline -concordant pharmacotherapy with an MI+CBT -CP 
intervention (Arm 2) have  lower pain interference  relative to the ir counterparts who receive guideline -
concordant pharmacotherapy integrated with SDM (Arm 1).  
2.3 Study Design  
Cross -reference: UNC IRBIS Application Section A.4.2.  
We will conduct a multisite, randomized pragmatic trial to examine the comparative effectivenes s of 2 
interventions : a guideline -concordant opi[INVESTIGATOR_467979] (Arm 1) compared 
with a guideline -concordant opi[INVESTIGATOR_467980] -CP (Arm 2). The study 
design is shown in Figure  1 and a CONSORT flow diagram shell is presented in Figure  2. 
Figure  1. Study Design  
 
 
2.4 Random Allocation to Treatment Groups and Blinding  
Cross -reference: UNC IRBIS Application Section A.4.3.  
This study will use real -time 1:[ADDRESS_599613] rained 
randomization approach ensures balance between treatment groups within each of the 3 institutions 
RandomizationTime 1 
Baseline 
measuresSDM 
Intervention
MI+CBT 
Intervention Study SampleTime 2 
6-month 
outcomes
T2
6-month 
outcomesTime 3
12-month 
outcomes
T3
12-month 
outcomesT4
18-month 
outcomes
T4
18-month 
outcomesCompare 
Outcomes
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Study Objectives  and Design  
Page 23 of 81 (our only stratification factor) at the completion of each block. Consequently, throughout the trial, the 
intervention arms are expected to have approx imately equal sample sizes both within an institution and 
across the study. We will not be able to blind participants or providers to intervention arm assignment 
because this is the nature of a real -world pragmatic trial.  
Figure  2. CONSORT 2010 Flow Diagram Shell
Assessed for eligibility after pre-screening review (n=...)
Excluded (n=…): 
• Did not meet inclusion criteria (n=…)
• Opi[INVESTIGATOR_467981] (n=...)
• Opi[INVESTIGATOR_467982] (n=...) 
• Suicide attempt within the past 3 years 
(n=...)
• Active suicidal ideation (n=...)
• Currently receiving CBT (n=...)
• Non-English speaking (n=...)
• Other reason at the discretion of the 
investigator (n=...)
• Other reasons (n=...)
• Declined to participate (n=...)
• Could not contact (n=...)
Randomized (target n=608)
Allocated to SDM intervention (target n=304):
• Received allocated intervention 
(n=...)
• Did not receive allocated intervention 
(give reasons) (n=...) Allocated to MI-CBT intervention (target 
n=304):
• Received allocated intervention 
(n=...)
• Did not receive allocated intervention 
(give reasons) (n=...)
Lost to follow-up (give reasons) (n=...)
Discontinued intervention (give reasons) 
(n=...)
Analyzed (n=...):
• Excluded from analysis (give reasons) 
(n=...)Lost to follow-up (give reasons) (n=...)
Discontinued intervention (give reasons) 
(n=...)
Analyzed (n=...):
• Excluded from analysis (give reasons) 
(n=...)Enrollment Allocation Follow-Up Analysis
 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Study Objectives  and Design  
Page 24 of 81 2.5 Study Duration  
Cross -reference: UNC IRBIS Application sections  A.4.2, A.4.[ADDRESS_599614] 72 months, from February 2018 to January 202 4. 
Enrollment is expected to  begin in April  2019 and will continue until enrollment has been completed , 
but no later than March 202 2, as shown in Figure  3. 
Figure  3. Study Timeline  
 
2.6 Study Enrollment and Number of Subjects  
Cross -reference: UNC IRBIS Application section A.4.2, A.2.1, A.2.3.  
Total anticipated enrollment is 608, with about [ADDRESS_599615] to enroll about 
203 participant s per institution.  However, there may be site -specific variation in recruitment to allow 
one or more institutions to recruit over 203 participants  to achieve the overall study target  of 608 
participants . We will not limit e ach institution to a prescribed maximum number of enrolled patients  
because some sites may be able to enroll more patients more efficiently than other site s but will adhere 
to any IRB guidance on maximum number of enrollees per institution . However, we will not enroll more 
than 608 participants across all 3 institutions.   
2.7 Study Population  
Cross -reference: UNC IRBIS Application  section  A.4.2, B.3.5.  
Participants will be from the Southeastern [LOCATION_002], a popula tion disproportionately impacted by 
[CONTACT_46248][INVESTIGATOR_15817]. T he trial will be conducted in primary care and specialty pain clinics at 3 university 
health  systems:  UNC , Duke, and  VUMC. These clinics have experience in opi[INVESTIGATOR_467983] h ave large populations of patients on COT. The 3 universities are part of the PCORNet 
Stakeholders, Technology and Research Clinical Research Network (STAR CRN), formerly known as the 
Mid-South CDRN.   
RTI was awarded funding from the Patient -Centered Outcom es Research Institute (PCORI) and is the 
data coordinating center . To the extent permitted under applicable law, RTI has full responsibility and 
liability for the conduct of the study and for the results reported . Prescreening, recruitment, screening, 
cons ent, and enrollment for the study will occur at primary care and/or pain specialty clinics at the 3 
participating clinical institutions.  

Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Study Objectives  and Design  
Page 25 of 81 2.8 Inclusion and Exclusion Criteria  
Cross -reference : UNC IRBIS Application: A.2.7 (age range) , A.3.1  (inclusion and exclusion criteria) , A.4.[ADDRESS_599616] meet all the following criteria:  
• Aged 18 to 85 years  
• History of CNCP  
• Receiving high -dose COT  for chronic non -cancer pain (CNCP)  as evidenced by  [CONTACT_468101] -equivalent dose (MED) of 20 mg or greater  for 
CNCP . Specific opi[INVESTIGATOR_467984] 3.  
• Receiving care at a participating clinic  from a participating provider , as evidenced by [CONTACT_2669] [ADDRESS_599617] 20 mg daily MED to be eligible for the study. If MED data are not 
available via the institution’s data warehouse, a proxy of [ADDRESS_599618] opi[INVESTIGATOR_467985].  
An individual who meets any of the following criteria will be excluded from participation in this study:  
• Not meeting the above inclusion cri teria  
• Opi[INVESTIGATOR_467986] a n active  cancer diagnosis  
• Opi[INVESTIGATOR_467940] ( OUD ) 
• Suicide attempt with in the past 3 years   
• Active suicidal  ideation  
• Currently receiving CBT  
• Non -English speaking  
• Other reason at the discretion of the investigator  
 
Self-report screening items that are not ascertained via medical record data are provided in the 
Participant  Screening and Consent Script  (see attached ).  
Two exclusion criteria perta in to past medical history: a) If the patient does not have a history of chronic 
non-cancer pain, they will be excluded; b) if the patient has a history of suicide attempt within the past 3 
years, they will be excluded. There is no exclusion based on accid ents or injury.  
Patients may be excluded for a limited set of other reasons based on the investigator’s discretion. It is 
difficult to anticipate the rare, often unique types of situations in which a patient may not be fit for the 
intervention and to develop specific exclusion criteria for each hypothetical instance.  
We include this discretionary category to allow inst itutions to handle rare cases in which patients would 
clearly be inappropriate for the study  such as : a) unstable behavior or b) cognitive impairment. If the 
patient is exhibiting clearly  unstable behavior or if the patient is clearly  not cognitively intac t the 
research coordinator will note this behavior during the screening process in this category. In addition, 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Study Objectives  and Design  
Page 26 of 81 the research coordinator will confirm this determination with the institution PI [INVESTIGATOR_467987]  a patient is excluded via a Case Re port Form (CRF) . While we recognize the limitations of 
subjective determinations, we do not want to burden respondents by [CONTACT_468102] a 
quantitative screening measure to assess the rare occurrence of unstable behavior or cognitive 
impairment.  
If institution policy requires blanket permission from each individual provider to recruit their patients, 
investigators at the site will contact [CONTACT_468103]. Clinicians at clinics 
participating in the INSPI[INVESTIGATOR_467988] h institution are told about study and that their patients may be 
recruited. None of these processes involve sharing any individual patient information. Patients whose 
providers opt -out of blanket permission to recruit patients will not be eligible and wil l not be contact[INVESTIGATOR_530].  
2.8.1 Clarification about Cancer -Related Pain Exclusion Criterion  
 If the patient has active cancer, then the patient is not eligible  if any of the following 3 are true:  
a) Opi[INVESTIGATOR_467989].  
b) The opi[INVESTIGATOR_467990], but it is expected that opi[INVESTIGATOR_467991].  
c) The opi[INVESTIGATOR_467990], but the patient’s clinician feels that bringing 
up the issue of ta pering would be emotionally upsetting. A tapering discussion might not be 
good for the patient at a time when the patient is already under a lot of stress.  
Otherwise, in a patient with active cancer  receiving chronic opi[INVESTIGATOR_2438], if the opi[INVESTIGATOR_467992] u sed to 
treat cancer -related pain, then the patient is potentially eligible.  
If the patient does not have active cancer  (i.e., it is in remission or “cured”), then they are potentially 
eligible for the study.  
If necessary, a final decision regarding e ligibility will be determined by [CONTACT_7880] [INVESTIGATOR_467993]’s clinician.  
2.8.[ADDRESS_599619] Substance Use Disorders  
Based on participating provider s’ input, we expect that  substance use disorder ( SUD ), including the use 
of “street narcotics,” will be uncommon in this population . Clinics are already responsible for screening 
patients on COT for SUD via urine drug testing (UDT), as per standard of care . As this is a pragmatic trial, 
clinics  will continue to test patients as they would normally . We will collect data  about SUD  diagnoses 
from the PCORnet CDM  to use as a covariate in the analyses . Generally, SUDs will not be an exclusion 
criterion ; as noted  above, the only exception will be when the opi[INVESTIGATOR_2480] (either buprenorphine or 
methadone) is being used for medication assisted treatment (MAT) for an OUD.  
Urine Drug Testing in Past Year  
If a patient has not had a UDT in the past year, they may receive testi ng during the study period as part 
of the standard of care. That is, t hey will not be excluded for not having had a UDT in the past year .  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Study Objectives  and Design  
Page 27 of 81 Opi[INVESTIGATOR_467994] , sometimes known as “pain contracts” are required for patients  on COT in 
some clinics. If a participant  does not already have a  treatment  agreement in place, they  may  be asked 
to sign one during the intervention  period . That is, they will not be excluded for not having a treatment 
agreement in place.  
Insurance Statu s 
Patients are not required to have insurance to be eligible for the study. However, we recognize that lack 
of insurance may  be a barrier to participation for some patients.  For this reason, we have provided 
additional information on the costs of participating in the study and that the uninsured may  have to pay 
for the costs of additional visits or CBT treatment, potentially on a sliding scale. If patients cite lack of 
insuran ce as a reason for refusing to participate or withdrawing from the study, we will record this as we 
would any other reason for refusal or withdrawal.  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Study Procedures  
Page 28 of 81 3 STUDY PROCEDURES  
A flow diagram of the study phases is presented in  Figure  4 with an explanation of each phase below.  
Figure  4. Study Phases Flow Diagram  
 
 
A summary of the study phases and pr ocedures prior to enrollment is provided in Table  1 and Table  2. 
Table  1. Pre -enrollment Study Phases, Procedures, and Materials  
Study Phase  Procedures  Patient -facing materials  
Prescreening 
(Identification of 
Potential 
Participants)  Extract recruitment phenotype data from 
local Research Data Warehouses  None  
Verify patient eligibility via EHR  None  
Recruitment  Recruit participants by [CONTACT_262909] e -mail  Recruitment Letter  
Recruitment Email Announcement  
Recruit participants by [CONTACT_468104]-person  Screening and Consent script  
Message Script  
Respond to questions using FAQ Guide  
Advertise study  Study Advertisement  
Study Brochure  
Study Posters  
Screening  Screen patients  Screening and Consent script  
Screening Consent  
Respond to questions using FAQ Guide  
Informed consent  Ask for informed consent  Study Informed Consent Form  
HIPAA Authorization  
Remote Enrollment Forms Emails  
 

Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599620] baseline data via self -report survey  T1 Survey  
T1 Emails  
Baseline Incentive Receipt Form  
Thank you letter with incentive  
Randomization  Allocate participants to intervention Arm 1 or 
Arm 2  None  
Intervention  Deliver guideline concordant care to 
participants in Arm 1 and Arm 2  None  
Deliver SDM intervention to participants in 
Arm 1  SDM Patient Materials  
Deliver MI+CBT -CP intervention to 
participants in Arm 2  CBT Session Sign -In Form  
MI+CBT -CP Patient Materials  
Intervention delivery based on MI -CBT 
Therapi[INVESTIGATOR_467995] -CBT Session Form  
Thank you letter with incentive  
Follow -up Collect baseline and follow -up data via clinical 
data extraction  None  
Collect 6 -month follow -up data via self -report 
survey  T2 Recruitment Materials  
T2 Survey  (web based  and CATI)  
Thank you letter with incentive  
Collect 12 -month follow -up data via self -
report survey  T3 Recruitment Materials  
T3 Survey ( web based  and CATI)  
Thank you letter with incentive  
Qualitative data 
collecti on (see 
section 3.9.3 
below)  Recruit participants  INSPI[INVESTIGATOR_467996]  
 
3.1  Identification of Potential Participants  
Cross -reference: UNC IRBIS Application A.9.1 (identifiers), A.9.2 , B.1.2 , B.1.3, B.2.1  (PHI and confidentiality) , C.1.1 
(data sources)  
Potential participants will be identified via each institution’s research data warehouse and electronic 
health records (EHR). Health Insurance Portability and Accountability Act (HIPAA) rules, other relevant 
federal or state laws, and local institutional r equirements will be followed, as applicable.  Study staff will 
upload this file into a local database for use in pre -enrollment study phases such as screening and 
recruitment (hereafter referred to as the Pre -enrollment database). Personally Identifiable In formation 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Study Procedures  
Page 30 of 81 (PII) and Protected Health Information (PHI) data in the Pre -enrollment database will stay at each 
institution.  
The study will collect a minimal set of information on patients who are identified, including those who 
are determined to be ineligibl e, refused, or unable to be reached. This will help to ensure transparent 
reporting, to meet CONSORT publishing requirements, and to respond to queries from regulatory 
authorities. Minimal information includes demographics, eligibility criteria, and reason s for 
nonparticipation. This information will be stored in the Pre -enrollment database.  
Information to be obtained via query of existing clinical data  includes the following : 
• Date of EHR query  
- The date on which the query was conducted  
• Patient contact [CONTACT_35865]  
- First name  
- Last name  
- Street address  
- City 
- State  
- ZIP code  
- Telephone number (cell, home, and work, if available)  
- E-mail  address  
• Other participant information  
- EHR unique identifier (medical record number)  
• Recruitment phenotype information  
- Date of birth  
- Name [CONTACT_468170]  
- Name [CONTACT_468171]  
- Date of last clinic visit  
- Date of next upcoming clinic visit  
- Daily MED for the most recent prescription  
- Number of opi[INVESTIGATOR_467997] 12 months. Includes these generic drugs 
and their brand  name [CONTACT_468172]:  
o buprenorphine  
o codeine and acetaminophen (not codeine alone)  
o transdermal fentanyl only  
o hydrocodone  
o hydromorphone  
o levorphanol  
o meperidine  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Study Procedures  
Page 31 of 81 o methadone  
o morphine  
o oxycodone  
o tapentadol  
o tramadol  
Note that we will not include pentazocine alone (Talwin) or 
pentazocine/naloxone  (Talwin Nx).  
• Opi[INVESTIGATOR_467998] 12 months  
- Order ID  
- Patient EHR uniqu e identifier  
- Provider name (prescription provider)  
- Prescription ordering date  
- Prescription name (generic name)  
- Form of drug (e.g., tablet)  
- Drug strength (dispensing units) (e.g., 100 mg)  
- Drug route of administration (e.g., oral , transdermal  – IV will not c ount ) 
- Dosing instructions  
- Drug dose (e.g., 1 capsule, 2 tablets)  
- Dose frequency (e.g., daily, twice daily)  
- Total number of units prescribed (quantity)  
- Number of refills  
• Patient demographic information  
- Gender  
- Race  
- Ethnicity  
3.2 Eligibility Screening  
Cross -reference: UNC IRBIS Application section s B.1.4, B.1. [ADDRESS_599621] of potential 
participants  and will identify potential participants meeting basic eligibility criteria (e.g. age, active 
patient status, opi[INVESTIGATOR_40533], and absence of exclusionary medical or psychiatric comorbidities). Research 
coordinators will verify whether they may be eligible for the  study .  
Then, potential participants will be contact[CONTACT_468105], who will introduce the study 
and invite them to complete a brief screening  in-person  or remotely . This is described in section 3.4 
below .  
3.3 Recruitment  
Cross -reference: UNC IRBIS Application  sections  B.1.1 , B.1. 5, B.1. 9 (contact [CONTACT_41528]) , B.1. 10 (roles), B.3.2 (number 
of contacts)  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Study Procedures  
Page 32 of 81 Research coordinators (RCs) at each institution will recruit potential participants . Physicians are not 
contact[CONTACT_468106]. The RC will follow a separate, detailed recruitment plan , 
the Recruitment Manual  (see Appendix ). This plan is briefly summarized below  and shown in Figure 5. 
More specific details are in the Manual.  
Any of the following methods that are IRB -approved m ay be used to approach patient s about the study : 
mail, e-mail , telephone,  study advertis ements , brochures, or in -person in the clinic. During recruitment, 
if the potential participant indicates interest, the RC will offer to conduct  screening in person  or 
remotely . If the patient refuses , the RC will make no further contact  [CONTACT_468107].   
The number of contact [CONTACT_468108]. Because this is a challenging 
study for recruiting patients (i.e., eligibil ity criteria and potential financial burden), we will minimize 
intrusion by [CONTACT_468109] [ADDRESS_599622] a voicemail on  the initial attempt if 
a patient is not home (see Message s Script  in the Appendix ). 
A patient may refuse to participate in the INSPI[INVESTIGATOR_208847].  If at any time, a patient indicates they do not 
want to be in the study (gives a hard refusal), the RC will stop contact[CONTACT_3018] . Refusals will be 
documented on the Recruitment  Log Case Report Form maintained at the institution; this does not go to 
RTI. Each  institution will be responsible for developi[INVESTIGATOR_007] a procedure to ensure that participants are not 
recruited more than once, and refusals are documented so that patients who refuse are not contact[CONTACT_468110].  
On a monthly basis , each instituti on will report aggregate consent status outcomes data using the 
Recruitment Summary CRF to the RTI Data Coordinating Center (DCC) via the web -based REDCap data 
management system. No identifiable data will be reported to the DCC.  Aggregate consent status 
outcomes will be reported to PCORI on a monthly  basis.  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599623] recruitment phenotype data
Sites identify patients through EHR research data warehouses using recruitment phenotype 
EHR Review
Research Coordinator (RC) checks the patient’s EHR to verify potential eligibility (e.g. opi[INVESTIGATOR_40533])
Recruitment (approach to assess eligibility)
• RC may approach the patient up to 6 times via mail, email,, phone, or in-person 
• At minimum, the RC will call all patients to discuss the study in more detail
• If the patient is interested in learning more, the RC will schedule an in-person or remote screening 
and enrollment visitClinician On-boarding
• Clinicians receive study overview and training 
• Clinicians give permission for researchers to contact [CONTACT_468111][INVESTIGATOR_208847] (if 
required by [CONTACT_14189]) 
Screening
• RC meets with patient in the clinic (Screening and Enrollment Visit) or remotely (via phone) 
• RC asks patient to sign Informed Consent for Screening
• RC conducts screening to verify eligibilityPre-Screening Enrollment
Consent
• RC asks eligible patient to read the Study Informed Consent Form 
• RC reviews the key points with the patient and conducts an Understanding Check 
• Eligible patient signs consent form if he/she agrees to participate
Baseline Survey
RC asks the participant to take the T1 Baseline Survey
Randomization
RC randomizes participant to Arm 1 or Arm 2
Intervention
• Patient receives more information about his or her assigned intervention
• RC coordinates visit schedulingAllocation
 
 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Study Procedures  
Page 34 of 81 We will implement the following strategies to increase  participant recruitment:  
• Each clinic will have a “clinic champi[INVESTIGATOR_2394]” (a practicing clinician who  has completed the necessary 
trainings and serves on the Study Advisory Committee [SAC]) onsite to provide clinic -specific 
advice on the consent and enrollment processes.  
• The RC will try to establish a connection with each potential participant and communicate 
proactively and respectfully to ensure that participants are comfortable in their understanding 
of the study intervention and processes, and that participation presents no undue burd ens. 
• All potential participants will be given IRB -approved materials that contain a toll -free number to 
call to ask additional questions or to opt -out of further study recruitment efforts if they choose.  
• Patient representatives from our SAC have review ed and provide d input on patient -facing 
materials.  
• The materials are written in plain language and at an appropriate reading level for a lay 
audience.  
• RCs will use a  Frequently Asked Questions (FAQ) Script  (see Appendix)  to help answer questions 
that may arise  in a consistent way  
• This population faces significant transportation barriers to accessing health care. To make the 
study more accessible, we will now offer remote enrollment and remote participation in t he 
intervention.  
• RCs may recontact [CONTACT_468112]. They  will see if they are interested in participating 
remotely .  
They  will only recontact [CONTACT_468113]. They  will 
not re -contact [CONTACT_468114], and they  will provide 
potential participants with the option to no longer be contact[CONTACT_468115].  
Strategies such as these will increase enthusiasm for the study among patients, providers, and clinic 
staff, which can help  promote successful recruitment.  
3.3.[ADDRESS_599624] potential study participants  by [CONTACT_2319] , e-mail, or both  to invite them to participate in the 
study. An IRB -approved  Recruitment  Letter (see Appendix),  which is the same content whether 
delivered by [CONTACT_65056], will tell  the patient about the study , and it will  ask them to  contact  [CONTACT_468116]. If the letter is returned as undeliverable, the 
Research Coordinator will attempt to confirm the patient’s address and resend the letter. If there is no 
response , a follow-up letter may be sent.  
3.3.2 Telephone Recruitment  
The RC  may use an IRB -approved Recruitment Script (see Appendix)  to call potential participants to 
recruit them for the study. The RC will follow a standard script to ensure consistency. The RC will 
confirm they are speaking with the patient, tell them briefly about the study, assess interest, and set up 
an enrollment appointment.  They will also offer the patient the option to enroll remotely. The remote 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Study Procedures  
Page 35 of 81 enrollment approach means that the RC will talk the pat ient through the enrollment process over the 
phone and email them links to electronic consent  forms  to complete screening and consent.  
As detailed in the Recruitment Manual (see Appendix) , if the patient does not answer the telephone, 
the RC will leave a brief message to request a callback; this message will not contain any information 
about the study or the patient’s health  (see Appendix for the  Message s Script) .  
3.3.[ADDRESS_599625] an IRB-approved Study Recruitment Ad  or Study Recruitment Poster  (see Appendix)  
within clinics , locally,  or online (including social media) to tell potential participants about the study . 
These materials will follow any institutional policies regarding the posting of study ads .  
3.3.4 Study Brochure   
The brochure will be used during recruitment. It will be given to patients by [CONTACT_464]. The intent of the 
brochure is to provide information to patients about the study. Text for the brochure was adap ted from 
the consent form and other IRB -approved participant -facing materials. All pi[INVESTIGATOR_467999] (no 
actual patients are pi[INVESTIGATOR_5832]).  
3.3.5 In-person Recruitment  
The RC  may approach potential participants  in-person at the clinic to tell them about the  study . The RC 
may use an IRB -approved Recruitment Script (see Appendix)  to approach  potential participants to 
recruit them for the study. RCs will follow a standard script to ensure consistency.  The Recruitment 
Script contains instructions for both in -person and phone recruitment.  
3.3.6 Provider Warm Hand -off 
The patient’s provider may briefly introduce the study to the patient during a clinic visit. This provides a 
chance for the patient to learn about the study and ask questions. Providers will use a standard set of 
Provider Talking Points (see Appendix)  to ensure consistency and to minimize undue influence or 
coercion. These talking points indicate that it is up to the patient to decide  that they will support the 
patient for their pain management no matter what they decide . If the patient is interested in the  study, 
the provider may make a “warm hand -off” to (i.e., introduce the patient to) an RC.  
A “warm hand -off” may occur during a telehealth appointment. T he recruitment coordinator may  
approach patients about the study during telehealth appointments, with the permission of the health 
care provider. Research staff will adhere to any institution or clinic policies regarding virtual patient 
appointments.  
3.4 Screening  
Cross -reference: UNC IRB IS Application section A.6.2 (steps to minimize psychol. risks)  
Participant  screening will occur in -person at the clinic  or remotely . The RC will follow the Participant  
Screening and Consent Script (see Appendix) . If the screening is conducted remotely, t he RC will do 
remote screening and enrollment over the phone with the patient, guiding  them through electronic 
forms  that are hosted securely at the clinical institution.  
Written or verbal  consent for screening will occur before eligibility scr eening is conducted.  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Study Procedures  
Page 36 of 81 If recruitment occurs in -person, p rior to study screening, the RC will ask the patient to sign the Informed 
Consent for Screening  (see Appendix) .  
If recruitment occurs remotely , we will make an adaptation to this process. The RC will  obtain consent to 
screen verbally by [CONTACT_468117] . All of the 
same information will be provided to the patient , and screening will only proceed if the patient tells us 
they understand and agree.  The study is collecting sensitive and personally identifiable information 
during the screening process. Depending on the responses to suicidal ideation questions, individuals 
need to be consented before screening activities occur. The informed consent for  screening clearly 
outlines what information will be shared, retained, and how it will be used.  
The study screening, provided in the  Participant  Screening and Consent Script (see Appendix) , asks 
about sensitive information, including: (1) whether the pati ent is receiving CBT currently, (2) is using 
opi[INVESTIGATOR_2480] s for pain due to cancer, and (3) suicide risk  ([ADDRESS_599626] indicates having thought about suicide recently). Suicide ideation includes both thoughts of 
being better off dead and thoughts of intentionally harming oneself .  
The research coordinator (RC) will invoke the INSPI[INVESTIGATOR_468000]’s Safety Protocol  (see Appendix)  if the 
patient expresses active  self-harm, if the patient has a positive screen on the suicide risk assessment , or 
if imminent self -harm or harm to others is suspected .  
The safety protocol requires  that the RC contact [CONTACT_468118] -site or on -call personnel 
(such as the prescribing physician , lead clinical investigator,  or other designated crisis responder, 
hereafter referred to as “designated responder”) to arrange for further assessm ent. If the designated 
responder cannot be reached, the RC will call [ADDRESS_599627] manager within 48 hours for further consideration of 
action and follow -up. IRB, DSMB, and/or PCORI will be notified as need ed.  
3.5 Informed Consent  
Cross -reference: UNC IRBIS Application section D.1 , A.3.2 (language)  
Once screened, eligible participants  will be asked to provide written or electronic consent to participate 
in the study. For remote consent, the RC will email the pa tient a link to the form and walk them through 
it verbally on the phone  (see Remote Enrollment Forms Email Templates in the Appendix).   
A consent form describing in detail the study intervention, study procedures, and risks will be given to 
the participant , and written or electronic documentation of informed consent is required prior to 
starting the intervention. The Study I nformed Consent Form  is submitted with this protocol  as an 
appendix . Each institution will have an approved form that is tai lored to their policies  and contact 
[CONTACT_3031] . The RC will also ask the individual to read and sign  (in writing or electronically)  a HIPAA 
Authorization Form (see Appendix) . Both of these electronic forms will be hosted securely at the clinical 
instituti on. 
It is outside the scope of the study to conduct the interventions in languages other than English. For that 
reason, we will not obtain consent in languages other than English.  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Study Procedures  
Page 37 of 81 3.5.1 Steps to Minimize Undue Influence during the Consent Process  
Cross -reference: UNC IRBIS Application section D.1.6  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the 
study and continues throughout the individual’s study participation. Consent forms will be Institu tional 
Review Board (IRB) -approved and the patient will be asked to read and review the document. Study 
staff will explain the research study to the patient and answer any questions that may arise. A verbal 
explanation will be provided in terms suited to t he patient’s comprehension of the purposes, 
procedures, and potential risks of the study and of their rights as research participants. Patients will 
have the opportunity to carefully review the written  or electronic  consent form and ask questions prior 
to signing.  To minimize coercion or undue influence, the researchers will encourage the potential 
subjects to review the consent forms in private. Patients will be encouraged to discuss the study with 
their family, provider, or others, or think about it prior  to agreeing to participate. The patient will sign 
the informed consent document prior to any procedures being done specifically for the study. Patients 
will be informed that participation is voluntary and that they may withdraw from the study at any time,  
without prejudice. All consent documentation will be written at a lay -friendly reading level. A copy of 
the informed consent document will be given to the participants for their records. The informed consent 
process will be conducted and documented in the  source document (including the date), and the form 
signed, either in writing  or electronically, before the participant undergoes any study -specific 
procedures. The rights and welfare of the patients will be protected by [CONTACT_468119] y of their medical care will not be adversely affected if they decline to participate in this study.  
Because of the nature of the interventions, we will not obtain surrogate consent for those unable to 
consent on their own behalf.  
3.6 Enrollment and Baseline  Data Collection  
Cross -reference: A.4.6 (data collection methods)  
Once a patient has signed the consent form, they will be considered enrolled in the study. Consented 
participants  will be asked to provide the following contact [CONTACT_3031] :  
• Salutation  
• First name  
• Middle name  
• Last name  
• Preferred name  
• Suffix  
• Mailing address, City, State , ZIP  code  
• E-mail address(es)  
• Phone number (s) – home, mobile , work, other  
• Reminder preference (e.g. , telephone, text message, e -mail, mail)  
• Information preference (e.g. , paper, electronic)  
• Contact [CONTACT_66178] (e.g. days and times)  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Study Procedures  
Page 38 of 81 Participants who enroll remotely can be asked to provide this information in an electronic form that will 
be hosted securely at the clinical institution (see Remote Enrollment F orms Email Templates in the 
Appendix).   
Patients who have consented to participate in the study will be entered into the study’s Enrolled 
Participant REDCap database hosted at RTI. Only information for consented participants will be stored in 
this database . The Enrolled Participant Database will include study status and participant data collected 
at and after enrollment.   
This study is not FDA regulated, so 21  CFR Part 11 compliance is not applicable.  
Participant s will be asked to complete the baseline  survey (T1) for assessment of patient -reported 
outcomes . The baseline survey may be self -administered electronically or verbally administered by [CONTACT_38992]  (or on paper if necessary). Participants can  complete  the survey  in-person at the clinic  or remotely . 
The T1 Baseline Survey is provided as an appendix . Participant s must complete the baseline survey 
before being random ly assigned  to the study  intervention.  
For remote administration, RCs  will send participants an email  with a private, secure survey link,  asking 
them to complete the survey  using the T1 Emails  template for  email invitations and reminders  (see 
Appendix) . 
3.7 Screen Failures  
Screen failures are defined as participants who consent to participate in the study  but are not 
subsequently randomly assig ned to the study intervention or entered in the study. For example, this 
could occur if a participant signs the consent form but does not complete the T1 baseline survey.  
A minimal set of screen failure information is required to ensure transparent report ing of screen failure 
participants, to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regulatory authorities. Minimal information includes 
demography, screen failure details, eligibility  criteria, and any serious adverse event (SAE).  
3.8 Randomization and Intervention Delivery  
After enrollment, participants will be randomly assigned to one of the two intervention arms  as 
described in Section 2.4. Interventions will be delivered as described in Section 6.  
3.9 Follow -up Assessment  Procedures  
Cross -reference: UNC IRBIS Application section A.4.4 , A.4.6, B.3.2 (number of contacts) , C.1.1 (data sources)  
We will use a comprehensive, multimode data collection method that includes the collection of patient -
reported outcomes through web -based and telephone approaches and leverage existing harmonized 
EHR data maintained by [CONTACT_468120].  
We will collect follow -up dat a in two ways:  
1. EHR data extraction from the PCORI Patient -Centered Clinical Research Network (PCORNet) 
STAR CRN .  
2. Patient surveys to collect patient -reported outcomes data.  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599628] while reducing delays related to data access and 
manageme nt. Data extraction and transfer procedures are described in section 10.2.1 below .  
3.9.2 Self-report Survey  
Follow -up assessments will include the coll ection of patient -reported outcomes data via self -report 
surveys  at two follow -up timepoints: [ADDRESS_599629] practices including that used by [CONTACT_468121] (BRFSS).67 
Introduction/Lead letter  or email  
One week prior to follow -up survey data collection at T2 and T3, RTI study staff will send a lead 
letter /email to enrolled participants . The purpose of the lead letter /email  is to remind the participants 
about the  follow -up survey s. The lead letter /email  can be found in the Appendix  (T2 and T3 Recruitment 
Materials document ) 
Web -based Administration  
RTI study staff will send p articipant s up to 4 emails over 4 weeks  with a private, secure survey link, 
asking them to complete the survey . Email reminders can be found in the Appendix (T2 and T3 
Recruitment Materials document. ) 
We will ask enrolled participant s to complete the surve y by [CONTACT_468122]  a) do not complete 
the follow -up Web -based survey within 4 weeks or b) do not have a valid email address.  
If a participant does not complete  the web survey after [ADDRESS_599630]  participants who  a) do not complete the follow -up Web-based survey 
approximately 4 weeks after the initial invitation or b) do not have a valid email address .  
For participan ts who do not have a valid email address,  we will make up to [ADDRESS_599631] is defined as when the caller reaches 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599632] telephone interviewing 
techniques  for Computer -Assisted Telephone Interviewing (CATI).  Phone scripts can be found in the 
Appendix ( T2 and T3 Recruitment Materials document).  
Mail  Administration  
Study staff  may mail participants a paper copy of the T2/T3 survey for the participant to fill out and mail 
back at no cost to the participant.  
Hard -To-Reach Protocol  
Before a pa rticipant is deemed lost to follow -up, study staff will make every effort to regain contact [INVESTIGATOR_240627] . 
RTI staff will use web -based location resources —such as search engines, Superpages.com, etc. —and will 
check with local site study staff to update contact [CONTACT_3031].  
RTI will notify the local site study staff of participants who cannot  be reached . The re search coordinator 
may follow -up with the participant to remind them about the survey and to set up an appointment time 
for RTI to call the patient to conduct the survey.  
Strategies for Retention  
Because the study involves enrollment over several months , we will use procedures to enhance 
participant retention , including  the following:   
• Using multiple  methods for contact[CONTACT_220379] . 
• Using s tudy reminders . 
• Providing i ncentives for survey completion and clinic visit attendance  (described below) . 
• Confirmin g current personal contact [CONTACT_468123] .  
• Giving patients an INSPI[INVESTIGATOR_467910] (see Appendix)  that 
summarizes their steps for taking part in their assigned intervention in one clear, easy -to-read 
page.  
• Sending a periodic newsletter to enrolled participants. The newsletters will include information 
such as survey and intervention reminders, backgr ound on what the study hopes to achieve, and 
stories from SAC members. Any  pi[INVESTIGATOR_468001] (no patients  or study 
participants  will be  pi[INVESTIGATOR_5832]).  Newsletter content will be submitted to IRB for approval.  
Additionally, institution leaders hip will meet regularly and obtain input from the SAC, which includes 
patient members,  to review and assess retention.  
3.9.[ADDRESS_599633] ing virtual individual interviews with participants in Arm 1 and  virtual  focus groups with those in 
Arm 2.  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599634] script ( See Attachments,  Qualitative Recruitment 
Materials ). During recruitment, the RC will confirm that the participant is willing and able to take part in 
a web conference call and will ask the participant upfront if they agree to be audio -recorded if they 
decide to participate.  
Informed Consent  
The RC will se nd the participant a confirmation email with a copy of the informed consent form ( see 
attachments, Informed Consent for CBT Participant Focus Group and Informed Consent for SDM 
Participant Interview).  
At the beginning of the qualitative session, the interv iewer will review key points of the informed 
consent with the participant(s) and ask if they have any questions. The moderator will ask each 
participant to provide verbal consent to participate and the notetaker will document the consent.  
Interview and Fo cus Group Administration  
An interviewer  and note -taker , both from RTI,  will facilitate the interviews and focus groups . The 
moderator will use a semi -structured moderator guide  (see attachments, CBT Focus Group Guide and 
SDM Interview Guide) to gather data  on participant experiences with the interventions, communication 
with their health care providers, pain management, and opi[INVESTIGATOR_2441]. We will conduct the  interviews  and 
focus groups  via a web conferencing platform. Each session will last up to 60 minutes. T o facilitate 
engagement, we will ask participants to turn on their video/webcam if able. For privacy and security 
reasons, we will not video record the session. We will only record audio from the session. We will use 
the audio recordings to create transcri pts, both of which will be stored on a password protected portion 
of the project share drive The RC will mail participants a $[ADDRESS_599635] at the conclusion of the focus 
group or interview as a thank you for their participation.  
3.10 Incentives for Study Parti cipation  
Cross -reference: UNC IRBIS Application section A.9.3  (SSNs), B.4.1 (incentives), B.4.2 (incentives)  
The following incentive will be provided for study participation:  
• Participants will receive a $30 incentive payment for completing the baseline sur vey.  
• Participants  will receive a $25 incentive payment for each follow -up survey completed .  
• Participants will receive  a $1 0 incentive payment for each group CBT -CP session completed.  
 
If the participant completes the T1 survey remotely or completes a group CBT -CP session remotely, the 
RC will mail them the incentive and Thank You Letter with Incentive (see Appendix) . The incentive 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Study Procedures  
Page 42 of 81 payments for the follow -up surveys will include the T2/T [ADDRESS_599636] could receive for either arm is under $200, therefore we are not 
collecting SSNs for payment.  Participants  receiving an incentive payment in person  will be asked to si gn 
a receipt form acknowledging receipt.  
If they choose to take part in the additional qualitative research activities, participants will receive a $75 
incentive payment for completing a qualitative interview or focus group.  
3.11 Study Completion  
The patient’s participation in the intervention  is complete  about  12 months after the completion of the 
T1 baseline survey ; participation in the study is complete after completion of the T3 survey.  
Key tracking data pertaining to visit  completion  and follo w-up completion will be captured. These 
tracking data will be used to coordinate the distribution of incentive payments to participant s and to 
identify trends in data collection; for example, to identify patterns of loss to follow -up that can inform 
outrea ch methods.  
3.12 Withdrawal  from the Study  
Cross -reference:  UNC IRBIS Application section A.7.3.  
Participants are free to withdraw from participation in the study at any time upon request. An 
investigator may discontinue or withdraw a participant from the stud y for the following reasons:  
• If any adverse event (AE) or other medical condition or situation occurs such that continued 
participation in the study would not be in the best interest of the participant . 
• Disease progression that requires discontinuation of the study intervention . 
• If the participant meets an exclusion criterion (either newly developed or not previously 
recognized) that precludes further study participation . 
The reason for participant discontinuation or withdrawal from the study will be record ed in the Enrolled 
Participant Database. The study will retain participant data collected prior to withdrawal. We will not 
contact [CONTACT_468124] -report data, and the participant will not receive any 
further intervention. However,  if the participant has completed any part of the intervention,  we would 
like to continue to extract the participant’s EHR data, and we will use the Withdrawal Consent 
Addendum  (see Appendix)  to seek permission to do so. If the participant withdraws prior to 
participating in the intervention, we will not collect any more of their data.  
3.[ADDRESS_599637] be taken if a participant fails to return to the clinic for a required study visit:  
• As this is a pragmatic trial, the clinic will follow standard clinical operating procedures for missed 
appointments. 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Study Evaluations and Me asurements  
Page 43 of 81 4 STUDY EVALUATIONS AND MEASUREMENTS  
4.1 Efficacy Evaluation  
4.1.1 Primary Outcome  
Opi[INVESTIGATOR_40533] , as measured by [CONTACT_468125], is the primary study outcome .68 The 
primary outcome will be examined at baseline and months 6, 12 , and 18 using opi[INVESTIGATOR_468002] 
(Table 3).  Prescribing data (including drug name, start and stop dates, dose, and frequency) will be 
derived from  the EHR and provided by [CONTACT_468126] (CDM). 
The field generally accepts prescribing data as documenting ingestion; other current and p reviously 
published studies also use prescribed dose as the primary endpoint.17,20,21,68 -72 However, we recognize 
that ingestion may not be the same as the prescribed regimen. We will analyze the absolute (primary) 
decrease (or increase) in opi[INVESTIGATOR_468003] (average of 90 days prior to 
randomization) until 18 months after  randomization. We also will examine percentage decrease. Total 
morphine equivalents for each prescription will be calculated by [CONTACT_468127] (milligrams of opi[INVESTIGATOR_468004]). Th e quantity -
strength product is then multiplied by [CONTACT_468128][INVESTIGATOR_468005].  The total average 
dose in morphine equivalents per day suppl ied is calculated by [CONTACT_468129] a given period and dividing by [CONTACT_468130].  
4.1.2 Secondary Outcomes  
The 2 secondary study outcomes, physical function and pain interference,  are based on patient self -
report  (Table 3).  These outcomes will be examined at baseline and months 6 and 12 . They will be 
measured using validated scales that are widely recognized in the pain literature as core outcomes.73 
Both of the secondary outcomes were selected with input from patients and in consultation with pain 
experts,74 and they are part of the Patient -Reported Outcomes Measurement Information System 
(PROMIS). PROMIS is a set of patient -centered  measures that evaluates and monitors physical, mental, 
and social health in adults and children. The PROMIS pain i nterference (PROMIS -PI) is an [ADDRESS_599638] validity. The PROMIS physical functioning 
(PROMIS -PF) is an [ADDRESS_599639] for comparative effectiveness research  in chronic pain . 
  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Study Evaluations and Me asurements  
Page 44 of 81 Table  3. Primary and Secondary Outcomes  
Domain  Outcome  Data Source  Title  # 
Items  Timepoints  Description  
 
Primary 
outcome:  
Clinical 
measure  Opi[INVESTIGATOR_468006]  n/a n/a Baseline 
and 
months 6, 
12, and 18  Average daily opi[INVESTIGATOR_468007] (MED).  
Key 
secondary 
outcomes:  
Patient 
Reported 
Outcomes 
(PROs)  Pain 
interference  Patient survey  PROMIS Short Form 
v1.0 – Pain 
Interference 8a  8  Baseline 
and 
months 6  
and 12 Assesses self -
reported 
consequences of 
pain on relevant 
aspects of one’s life. 
5-point Likert 
scale .74 
Physical 
function  Patient survey  PROMIS Short Form 
v1.0 -- Physical 
Function 8a  8  Baseline 
and 
months 6  
and 12  Assesses self -
reported capability 
rather than actual 
performance of 
physical activities. 5 -
point Likert scale.75 
Note: MED = morphine equivalent dose; PROMIS = Patient -Reported Outcomes Measurement Information System  
4.1.3 Other Self -Reported Outcomes  
We will obtain additional self -reported outcome measures regarding pain intensity  (both verbal  5-point 
Likert scale and numeric 10-point scale ratings)  and numeric rating of physical function using the 
PROMIS pain intensity scale  and may also use the 11 validated  items of the Brief Pain Inventory (BPI) 
(Table 4 ).[ADDRESS_599640] difficulty completing 
one of the ratings.73  
Chronic pain is often accompanied by [CONTACT_468131], anxiety, and depression,73 and for this reason, 
we will  measure anxiety and depressive symptoms  at baseline, 6, and 12 months  using PROMIS 
measures.  
Intent to taper  will be measured via self -report  at baseline and months 6 and 12. The follow -up 
assessments at months 6  and 12 will also include a self -report measure of relative opi[INVESTIGATOR_2441] (no longer 
taking opi[INVESTIGATOR_2438], higher dose than baseline, or lower dose than baseline) .  
Covariates will  include demographic characteristics, health insurance status, health  literacy level , and 
patient -centered communication . Age, gender , race, and ethnicity  will be included on the baseline 
survey. These self -report variables will be cross -referenced to EHR-derived data  to confirm alignment of 
the two data sources.  
  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Study Evaluations and Me asurements  
Page 45 of 81 Table  4. Additional Self -Reported Outcome Measures  
Measure  Title  # Items  Timepoints  Description  
Pain Intensity  
(verbal rating)  PROMIS Scale v1.[ADDRESS_599641] item for asks patients to rate their pain 
intensity “right now.” 77 
Pain Intensity 
(numeric rating)  Brief Pain Inventory 
(BPI) – pain 
intensity sub -scale  [ADDRESS_599642] week, with responses on a numeric 
scale of 0 to 10.76 
Pain Interference 
(numeric rating)  Brief Pain Inventory 
(BPI) pain 
interference sub -
scale  [ADDRESS_599643] week, with responses on a 
numeric scale of 0 to 10.76 
Emotional 
distress 
(Anxiety)  PROMIS —Anxiety, 
4-item Shor t Form  4 Baseline, 
months 6 
and 12  Assesses generalized anxiety/distress over 
the past 7 days. 5 -point Likert scale. 78 
Depressive 
symptoms  PROMIS Short Form 
v1.0 – Depression 
4a [ADDRESS_599644] 
7 days. 5 -point Likert scale.78 
Demographic 
characteristics  n/a 8 Baseline  Age, race, ethnicity, assigned sex at birth, 
gender identity , education, marital status, 
and employment status  
Health insurance 
status  n/a 1 Baseline, 
months 6 
and 12 This item  assesses if a patient has health 
coverage  and what type  
Health literacy  Health Literacy 
Skills Instrument 
(HLSI)  4 Baseline  Assesses the patient’s understanding of 
health information.  
Patient -centered 
communication   Patient -centered 
communication  6 Baseline, 
months 6 
and 12  Assess the patient’s experience with care 
and communication  
 
4.1.4 Other EHR -Derived Outcomes  
Cross -reference: UNC IRBIS Application section A.9.1  (identifiers) . 
Other measures collected through the PCORnet CDM include:  
• Demographic information (birth date, sex, race, and ethnicity)  
• Patient height and weight  
• Health care provider information  
• Death in formation (death date and source)  
• Health care visit information ( visit dates, primary payer, facility type, and provider ID)  
• Diagnosis and condition information (condition data and type, diagnosis dates, and associated 
ICD/CPT codes)  for:  
▪ Mental health di sorders, defined by [CONTACT_48334] -10 codes (e.g., depression, anxiety, 
schizophrenia, bipolar disorder, suicide attempt/intent)  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Study Evaluations and Me asurements  
Page 46 of 81 ▪ Number and type of CNCP conditions per ICD -10 codes (e.g., back pain, neck pain, 
headache, arthritis, HIV)  
▪ Alcohol/substance misuse or abu se as measured by [CONTACT_48334] -10 codes.  
• Overall comorbidity using the Charlson Comorbidity Index  per ICD -10 codes79 
• Opi[INVESTIGATOR_468008] (drug prescribed), prescription dates, 
dose, units, frequency, route, quantity, refills, and supply days.  
 
We will calculate time to discontinuation of opi[INVESTIGATOR_2438], where discontinuation will be measured based on 
our previ ous work,20,[ADDRESS_599645] day of a minimum 90 -
day period with no o pi[INVESTIGATOR_75155] (see Section 5.2 for additional information about the definitions 
and analyses).  
A Schedule of Assessments indicat ing the timing and source of efficacy, safety, and fidelity measures  is 
presented in Table 6.  
4.2 Safety Evaluations  
See Section 8 for information about the study’s safety evaluations and procedures.  
4.3 Process Evaluation  
Cross -reference: UNC  IRBIS Application section A.9.1 (identifiers).  
The research team will develop a set of intervention fidelity measures to assess the extent to which the 
intervention was implemented as planned. The research team will evaluate fidelity  via: EHR 
documentation  review  with a random sample of notes , clinical  data extraction, and patient self -report. 
The measures are described in  Table  5.  
Table 5. Process Evaluation  
Evaluation  Measure  Data Source  
SDM intervention 
fidelity  Extent to which patients read or viewed 
SDM materials  Patient self-report (T2 and T3 surveys)  
Number of visits to an SDM -trained 
provider during the intervention period  Extracted from EHR using intervention -
specific templates   
Visit status data entered into REDCap  by 
[CONTACT_468132] -specific templates  
MI+CBT -CP 
intervention fidelity  Number of intervention sessions 
attended  CBT session attendance l ogs which will be 
entered as visit status data in REDCap  by 
[CONTACT_468133] -specific templates  
Opi[INVESTIGATOR_468009] (GCC) 
fidelity  Elements of GCC covered, e.g. the 
patient has had a UDT within the past 12 
months, Prescription Drug Monitoring 
Program [PDMP] was checked  Provider report via EHR encounter notes  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
 
Study Evaluations and Me asurements  
Page 47 of 81 Table 6. Schedule of Assessments  
Measurement  Screening  
(Month -12 to 
0) Enrollment/ 
Baseline 
Survey  
(Month 0)  Baseline 
Clinical Data 
Extraction  
(Month -3 to 
0) Intervention 
visits  
(Months 1 -12) Clinical Data 
Extraction  
(Months 6, 12, 
18) T2 follow -
up survey  
(Month 6)  T3 follow -up 
survey  
(Month 12)  Qualitative 
research 
activi ties 
Informed consent  ●       ● 
Demographics   ● ●      
Randomization   ●       
Average daily opi[INVESTIGATOR_40533]    ●  ●    
Charlson Comorbidity Index (ICD -9/10)    ●      
Chronic noncancer pain conditions (ICD -9/10)    ●      
Mental health disorders (ICD -9/10)    ●      
Alcohol/substance use disorders (ICD -9/10)    ●      
Body mass index (based on height and weight)    ●      
Health insurance payer   ● ●  ●    
Opi[INVESTIGATOR_468010]    ●  ●    
Study intervention intensity (based on number of 
intervention visits)      ●    
PROMIS self -report scales: (Pain Interference, 
Physical functioning, Pain Intensity, Anxiety, 
Depression)   
●  
  ● ●  
Brief Pain Inventory (11 key items)   ●    ● ●  
Health literacy level   ●       
Patient centered communication   ●    ● ● ● 
Self-reported relative opi[INVESTIGATOR_2441]       ● ●  
Intent to taper   ●    ● ● ● 
Use of intervention content       ● ● ● 
Satisfaction with care   ●    ● ● ● 
Adverse Events and death review and evaluation    ● ● ● ● ●  
Fidelity review and evaluation     ●  ● ●  
Cross -reference: UNC IRBIS Application section A.9.1 (identifiers).  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Statistical Consideration s 
Page 48 of 81 5 STATISTICAL CONSIDERATIONS  
5.1 Summary of Statistical Analysis  
Cross -reference: UNC IRBIS Application section A.8.1.  
Statistical analyses for this study have been designed to compare (1) the effectiveness of the 2 
interventions (MI+CBT -CP and SDM) in reducing opi[INVESTIGATOR_468011] , and (2) the 
effects of the [ADDRESS_599646] the primary 
hypothesis that the reduction in op ioid dose  (absolute change in MED)  differs between the [ADDRESS_599647] 
intervention arm differences for 2 key secondary outcomes: change in pain interference and physical 
function at 12 months. Change in outcomes at 6 months will be described. Primary and secondary 
analyses will use model -based approaches that take advantage of  the longitudinal structure of the 
outcome data to address missing data caused by [CONTACT_468134] -up or nonresponse.  
The primary analyses will be based on the intention -to-treat (ITT) principle, with data from all 
participants analyzed according to the arm to which they were randomized irrespective of intervention 
received, as will key secondary analyses of pain interference and function. As in most clinical trials, some 
participants in this trial may not adhere to the intervention they were allocate d to receive or comply 
with the intervention as prescribed, reducing fidelity to the intervention as designed and potentially 
changing the effectiveness of the intervention. The most likely form of noncompliance will be absence 
from group therapy sessions in the MI+CBT -CP arm or with patients on the SDM arm ceasing interaction 
with the assigned  provider . The potential impact of this noncompliance is the dilution of the true 
treatment effect. In addition to the ITT analyses described above, we will conduct s econdary analyses 
using a per protocol population that received a substantial portion of the randomized intervention, 
defined as at least [ADDRESS_599648] 4 MI or CBT sessions. Details of the definition of this per 
protocol population will be pr ovided in the Statistical Analysis Plan . The analysis plan will be drafted 
prior to the receipt of the initial PC ORnet data extraction (Section 2.6 ) and  finalized prior to REDCap 
study database lock and the final PCOR net data extraction.   
Secondary analyse s also will explore differences in the intervention effect according to participant 
characteristics, such as age, health literacy level, patient -centered communication, baseline pain level, 
baseline opi[INVESTIGATOR_40533], body mass index, and the presence of physica l comorbidities, mental health 
comorbidities, or a history of substance abuse.  
One single primary formal hypothesis test is planned for this study at the 0.05 level of significance, 
which is the comparison of the intervention arms for the primary outcome a t the primary timepoint.  
Additionally, regardless of significance of the primary outcome, statistical significance of the 2 key 
secondary outcomes will be assessed, with adjustment for multiple comparisons using the Hochberg 
modification to the Bonferroni adjustment .80 Primary and secondary hypothesis tests resulting in 
nonsignificant p -values will be interpreted as i nconclusive. All other treatment group comparisons will 
be considered descriptive in nature with no adjustment for multiple comparisons, and all confidence 
intervals will be generated using 95% bounds.  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Statistical Consideration s 
Page 49 of 81 5.2 Study Endpoints   
5.2.1 Primary Endpoint  
The primary outcome for this study is the absolute change in opi[INVESTIGATOR_40533] (in MED) from baseline at [ADDRESS_599649] -
randomization periods, change in daily opi[INVESTIGATOR_468012]. Although the primary 
outcom e is the change at 12 months (with secondary timepoints at 6 and 18 months), analyses will be 
based on a linear mixed model using data from all 4 - through 18 -month time periods to account for 
missing data and thereby [CONTACT_468135]. Percentage change in 
MED from the baseline period also will be evaluated in a secondary analysis focusing on key clinical 
dosing thresholds. The distribution of opi[INVESTIGATOR_468013], 
and if opi[INVESTIGATOR_2495] d dose change from baseline is determined to be highly skewed and substantially non -
normal, then opi[INVESTIGATOR_468014], and the primary analysis will 
compare the intervention arms based on the relative dose reduction . Details of the algorithm used to 
calculate milligrams daily MED and for modelling the primary outcome measure will be provided in the 
Statistical Analysis Plan.  
5.2.2  Key Secondary Endpoints  
We will examine 2 key secondary effectiveness endpoints: (1) change from baseline in self -report of pain 
interference at 12 months, and (2) change in self -report of physical functioning at [ADDRESS_599650] deviation (SD) of that population . 
A concern frequently expressed by [CONTACT_468136] a reduction in physical function that can be 
associated with both the chronic pain and opi[INVESTIGATOR_2441]. For this study, we will measure physical 
functioning using the [ADDRESS_599651] deviation (SD) of that population.  
5.2.3 Other Endpoints  
Other effectiveness endpoints include self -report of pain intensity, anxiety, depressive symptoms,  and 
PROMIS pain intensity . Outcomes are defined as the change in T -score based on the PROMIS norma tive 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Statistical Consideration s 
Page 50 of 81 population from baseline to 6 and 12 months.  The 4 items within the Brief Pain Inventory (BPI) pain 
intensity subscale are analyze d individually , and a summary measure is calculated as the average of the 
items. The [ADDRESS_599652] prescription 
(generally 30 days) and continuing until study completion at [ADDRESS_599653] prescription to be considered an opi[INVESTIGATOR_468015]. The day of opi[INVESTIGATOR_468016] -out date (generally 30 
days) after the last opi[INVESTIGATOR_16447]. Participa nts who have a prescription within 120 days (or 
prescription run -out within 90 days) prior to study completion at 18 months (or the last data extraction), 
or have not been seen in clinic for [ADDRESS_599654] recorded opi[INVESTIGATOR_16447] (generally 30 days) and included in the time to opi[INVESTIGATOR_468017] a censored outcome using standard statistical procedures. Additional details 
of the computation of this outcome measure will be included in the Statistical Analysis Plan.  
Safety outcomes for this pragmatic open -label intervention trial are limited to SAEs  and are noted in 
Section 8. 
5.2.[ADDRESS_599655] the hypothesis  that this reduction differs between the 2 intervention arms.  While 
the primary and secondary time  assessments  are at 6, 12 and 18 months, all available opi[INVESTIGATOR_468018] 18 months will be included in the model.  This approach will 
provide consistent estimates and valid inferences under missing at random (MAR) data assumptions 
while accounting for correlation among multiple measures on the same participant. This mixed model 
will improve the power of the study and t he precision of all estimates by [CONTACT_468137], even if other timepoints are missing. The model will 
include fixed effects for the treatment group, time interval (as a categorical varia ble), treatment -by-time 
interaction, baseline opi[INVESTIGATOR_40533], the stratification effect of institution , and random effects for 
participant. An intervention -arm‒specific Toeplitz correlation structure will be assumed for the within -
participant measures, to ref lect the changing correlation of these measures over time and permit the 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599656] differences in mean changes in opi[INVESTIGATOR_468019] 2 intervention 
groups at 12 months (primary timepoint) and to generate point and interval estimates at 6 and 18 
months (secondary timepoints).  
This model treats missing data as ignorably missing, assuming any missing data are missing at random , 
after accou nting for baseline opi[INVESTIGATOR_40533] . Sensitivity analyses based on multiple imputation procedures 
will be performed to evaluate departures from critical distributional and missing data assumptions. 
Plans to address missing data are further presented below (see Missing Data  Section)  and will be 
described in detail in the Statistical Analysis Plan.  Assessments of model assumptions and goodness -of-
fit will also be specified in the Statistical Analysis Plan . 
5.3.[ADDRESS_599657] of potentially important covariates for both the ITT and the per protocol populations.  
PROMIS Pain Interference and Physical Functioning  
Secondary analyses will generate point and interval estimates of mean change in physical function as 
measured by [CONTACT_941] 8 -item PROMIS -PF scale and mean change in pain interfer ence as measured by [CONTACT_941] 8 -
item PROMIS -PI [INVESTIGATOR_468020] 6 and 12 months and  point and interval estimates of the mean 
difference between the 2 intervention arms. These secondary analyses will use appropriate linear mixed 
model -based approaches analogous to those described for the primary outcome analysis.  
Other secondary outcomes (PROMIS anxiety, PROMIS depression, and BPI [INVESTIGATOR_468021] n 
interference will be analyzed similarly.  
We will explore the percentage of participant s per group who experienced an in crease in pain and a 
decrease is in dose.  Additional analyses will compare the treatment groups for the incremental impact 
of opi[INVESTIGATOR_468022] -reduction per unit change in pain interference and physical functioning score.  
Incidence of self -reported intent to taper opi[INVESTIGATOR_2536], collected at baseline, [ADDRESS_599658] ratio 
comparing likelihood of opi[INVESTIGATOR_468023].  
Safety Analysis for Adverse Events  
Each of the safety  outcomes describe d above can be characterized as a binary outcome. For each 
measure, contingency tables will be generated that summarize the risk of occurrence by [CONTACT_468138]. Because AEs are expected to be relatively rare, contingency table methods will be used to generate 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599659] binomial confidence limits. Cochran -Mantel -Haenszel tests stratified by [CONTACT_941] 3 clinical 
institutions  will be used to  generate p -values that assess potential differences in odds ratios by 
[CONTACT_105150].  
Assessments of Intervention Adherence and Fidelity  
Adherence and fidelity of the intervention arms in terms of both the average amount of planned 
intervention received  by [CONTACT_468139] (as assessed by [CONTACT_468140]) will be described overall and 
will be compared across the time -course of the study and between  institutions  with descriptive 
statistics. Fidelity of GCC, to be provided in each of the  intervention arms, also will be compared 
between intervention arms. Details for these analyses will be provided in the Statistical Analysis Plan.  
5.3.3 Other Analysis Considera tions  
Subgroup Analyses (Heterogeneity of Treatment Effect)  
While multiple subgroup analyses have an inherent risk of inflating  Type I error, this trial offers a unique 
opportunity to generate hypotheses about the profile of patients most likely to benefit from the 
intervention. Consequently, planned secondary analyses will assess potential differential treatment 
effects for two subgroup s: 1)  defined by [CONTACT_468141] 2) sex . 
Descriptive testing of the heterogeneity of treatment effect, which is meant to be hypothesis 
generating, will be established based on the interaction test from a mixed  effects model in which the 
subgroup variable and an intervention arm by [CONTACT_468142] [ADDRESS_599660] according to age, 
baseline pain score, comorbidities (including physical comorbidities and mental health disorders, and 
past or current alcohol or other substance abuse and related di sorders), those taking other medications, 
patient health literacy level, BMI, and opi[INVESTIGATOR_468024] 3 categories consistent with CDC 
guidelines: low (20 -49 MED), moderate (50 -89 MED), high (90 or more MED).  Testing for heterogeneity 
of treatm ent effects for these subgroups will be considered exploratory as opposed to confirmatory, and 
the results will be interpreted with appropriate caution.  Heterogeneity of effect based on receipt of 
intervention by [CONTACT_468143] -person, and based on c ategorized number of intervention sessions 
received will be similarly explored.  
Missing Data  
The study will implement multiple procedures to prevent and reduce the amount of missing data and 
use appropriate statistical procedures to evaluate whether the re sults are robust to missing data. The 
risk of missing patient -reported outcome measures has been reduced by [CONTACT_468144] “short” versions of instruments to 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Statistical Consideration s 
Page 53 of 81 reduce burden.  It is possible , however, that there may be some  nonresponse to the 6 - and 12-month  
patient reported outcome surveys . The sample size calculation assumed as high as 25% non -response at 
[ADDRESS_599661] 
PCORnet data extraction procedures , yet sample size calculations allow for up to 12% missing data at [ADDRESS_599662] awal of  consent  for use of EHR data . To reduce 
the risk of being unable to calculate the primary outcome because of missing or uninterpretable dosing 
instructions, MED will be derived using only the standardized and highly accurate fields: drug name, 
strength, and number of pi[INVESTIGATOR_3353]. In the ev ent of missing medication information for a prescription (such as 
strength or number of pi[INVESTIGATOR_3353]), we will impute medication information from the [ADDRESS_599663] to follow -up within the 
EHR or withdrew consent for study participation to identify possible differential attrition. For primary 
and secondary outcomes analysis, the planned likelihood -based analysis will produce unbiased results if 
the data are MAR; that is, not related to the unobs erved value of the outcome, but can be related to 
observed values of the outcome or model covariates.  
Although the MAR assumption is often reasonable, in this study it will be possible that even after 
controlling for other correlates of missingness and out come data observed before participants are lost, 
likelihood of attrition may be associated with key outcomes of interest, including opi[INVESTIGATOR_2441], physical 
function, and pain interference. Consequently, sensitivity analyses to the MAR assumption based on 
mult iple imputation strategies to include control -based imputation as well as tippi[INVESTIGATOR_007] -point analysis will 
be described in the Statistical Analysis Plan.  
5.4 Sample Size and Power  
Cross -reference: UNC IRBIS Application Section A.8.3.  
Sample size estimates were gen erated to provide robust power to detect minimal clinically important 
differences (MCID) in reduction of opi[INVESTIGATOR_372436] 2 study arms . 
Based on anecdotal information from the clinics participating in the study and data available from the 
Liebschutz84 and Sullivan et al.64 studies, a reasonable estimate of mean baseline opi[INVESTIGATOR_173668] e across the 
planned study is 55 mg/day. Based on doses of this magnitude, providers involved with the study 
indicated that differences in dose reduction of [ADDRESS_599664] size of a difference 
of 10 MED between the 2 intervention arms. The data available from the Liebschutz84  and Sullivan et al. 
64  studies indicate that a reasonable estimate of the coefficient of variation (ratio of standard deviation 
to the mean) for opi[INVESTIGATOR_468025] 1.45 (range of  1.19 to 1.54), suggesting that a reasonable estimate 
for the standard deviation of the dose level for this study is [ADDRESS_599665] of treatment differences in the change in opi[INVESTIGATOR_468026]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Statistical Consideration s 
Page 54 of 81 than 50% of th e baseline level, or 40 mg/day. Based on these assumptions and an assumed minimally 
important difference of 10 mg/day, the number of evaluable independent participants required to 
achieve 80% power to detect a difference of this size is approximately 253 per study arm  (total of 506), 
assuming no attrition . 
The data available from Liebschutz84 and Sullivan  et al. 64  indicate opi[INVESTIGATOR_468027] (ln) scale. If the change from baseline in opi[INVESTIGATOR_468028], then based on the assumptions above the standard deviation of the change 
from baseline ln -dose, after adjusting for baseline dose would be appro ximately 0. 650. Correspondingly, 
253 participants per study arm provides 80% power to identify a 15% relative dose reduction.  
To account for potential variance inflation associated with CBT group delivery (based on a group size of 
8 and an interclass corre lation coefficient of 0.01) and a potential loss of follow -up information on as 
many as 10% to 12% of participants because of attrition, the sample size was inflated by 20% to yield a 
total randomized size of 304 per study arm  needed for the primary outcome  at 12 months. Therefore, 
the total study sample size will be 608 randomized participants  (Table 7).  
Additional estimates  of sample size requirements were generated based on the known psychometric 
properties of the secondary outcomes , PROMIS physical functioning and pain interference,  under the 
assumption that at least 80% power is desired for  the PROMIS Pain Interference sc ales. The scoring 
algorithm for the PROMIS scales is designed to construct a [ADDRESS_599666] deviation of 10. Furthermore, studies of the properties of the instruments indicate that the 
minimally important difference (MID) fo r the physical function scale is 2 units, whereas the MID for the 
pain interference scale is 3.5 units. Under an assumption of independent observations, a sample size of 
786 evaluable participants would be required to achieve 80% power to detect the MID of  2.0 units for 
the physical function scale, and a sample size of 260 evaluable participants would be required to achieve 
80% power to detect the MID of 3.5 units for the pain interference scale . With the planned total of 608 
randomized participants, the power for the PROMIS Pain Interference score is 96%, while the power for 
the PROMIS Physical Functioning scale is 57%, with a 25% increase to account for attrition or missing 
PROMIS scale responses . No power calculations have been specified for subgroup assessments ( Table 
8). 
A review of the opi[INVESTIGATOR_468029] a is normally distributed or 
skewed and thus requires log transformation prior to analysis . If the change in MED is highly skewed, 
analyses will compare intervention arms for relative rather than absolute dose reduction. The study has 
comparable power to i dentify a 15% relative dose reduction between intervention arms.  
  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Statistical Consideration s 
Page 55 of 81 Table 7. Sample Size Required to Obtain 80% Power for Primary and Key Secondary Outcomes  
Parameter  Mean 
difference 
between 
groups for 
change from 
baseline  SD Power  N  
(total)  Percentage 
increase to 
account for 
1-year 
attrition and 
within -cohort 
correlation  N with 
increase for 
attrition*  
Average Daily 
MED  10 40 80%  506 20%  608 
PROMIS Pain 
Interference 
Scale  3.5 10 80%  260 25%  350 
PROMIS 
Physical 
Functioning 
Scale  2 10 80%  786 25%  1060  
*The n is increased by 20% in the calculation to account for expected within -cohort correlation and attrition from 
the study before the primary 12 -month timepoint. A further 5% attrition was assumed for the PROMIS s cales 
collected via web or phone.  
 
Table 8. Power for Primary and Key Secondary Outcomes with N=608 Randomized Participants  
Total sample 
size Primary aim:  
Power for opi[INVESTIGATOR_468030]*  Secondary aim: power for 
PROMIS Pain Interference*  Secondary aim:  
Power for PROMIS Physical 
Functioning*  
608 80%  96%  57%  
*MID, SD, and loss to follow -up rates are the same as noted in  
Table  7. 
 
5.[ADDRESS_599667] (DSMB) will routinely monitor the study for safety, conduct, and 
fidelity assessments of GCC, SDM, and CBP -MI with details of the monit oring approach specified in the 
DSMB Charter  (see Appendix) , the Data and Safety Monitoring Plan (DSMP), and the Statistical Analysis 
Plan. The DSMB will not formally monitor efficacy or effectiveness outcomes for purposes of stoppi[INVESTIGATOR_311306] (eith er due to demonstrated efficacy or futility).  
  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Study Intervention  
Page 56 of 81 6 STUDY INTERVENTION  
Cross -reference: UNC IRBIS Application Section B.3.5.  
This section describes the 2 interventions we will compare for managing CNCP patients on COT: a 
guideline -concordant pharmacotherapy approach with SDM (Arm 1) compared with a guideline -
concordant pharm acotherapy approach with MI and CBT for chronic pain (Arm 2).  Both arms of the 
intervention will be integrated into the usual workflow of the clinics. The first three months of the SDM 
intervention are the most intensive, similar to how the first three mon ths of the CBT arm are the most 
intensive.  
Participants in each of the study arms will receive guideline -concordant care (GCC), based on CDC 
clinical guidelines for COT for CNCP at their opi[INVESTIGATOR_468031] [ADDRESS_599668] research participants, 
researchers, and the larger community from risk of infection .  
Participant research visits will be performed remotely when appropriate and possible , via phone or 
telehealth/telemedicine . Telehealth services used will meet the study’s security level clearance.  The 
content of the interventions in the study will remain u nchanged.  Each institution will work with their IT 
departments to ensure they are using the telehealth services according to the institution’s policy.  
Participants who are currently enrolled in the trial will be given information about the change, the 
reasons for the change, and how the changes may impact their research activities. We will notify 
participants of the changes via phone call, letter, email, etc. and we will document how we notified 
them  (see attached, Information for Participants on the INSPI [INVESTIGATOR_468032] -19).  
6.1 Guideline Concordant Care  Intervention  
CDC guidelines for treating adult patients for chronic pain in outpatient settings were developed to 
“improve communication between clinicians and patients about the benefits and risks of usin g 
prescription opi[INVESTIGATOR_75148]; provider safer, more effective care for patients with chronic 
pain; and help reduce opi[INVESTIGATOR_459091].” As a guideline for providers, the intervention 
content is primarily directed toward the pro viders participating in the study.  The guidelines give 
guidance about medication selection, dose and duration, when and how to assess progress, and 
discontinue medication if needed. They support the patient -provider team to jointly assess the benefits 
and risks of prescription opi[INVESTIGATOR_2441].  Participants in each study arm will receive guideline -concordant 
pharmacotherapy treatment, based on clinical guidelines for opi[INVESTIGATOR_467938].  
GCC specifies current best practices for  primary care providers who are  treating COT. The best practices 
include the following:  
• Determining when to initiate or continue opi[INVESTIGATOR_75163]  
- Not using opi[INVESTIGATOR_468033] -line therapy (not applicable in this study, as participant s will 
already be taking opi[INVESTIGATOR_2438])  
- Establishing g oals with the patient for pain and function  
- Discussing risks and benefits  with the patients  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Study Intervention  
Page 57 of 81 • Determining opi[INVESTIGATOR_468034], dosage, duration, follow -up, and discontinuation  
- Using immediate -release opi[INVESTIGATOR_468035] (not applicable if participant s are 
already taking opi[INVESTIGATOR_2438])  
- Using the lowest effective dose  
- Prescribing short durations for acute pain  
- Evaluating benefits and harms frequently  
• Assessing risk and addressing harms  
- Using strategies to mitigate risk —including patient risk assessment for prior SUDs  and 
offering naloxone if increased risk or concurrent benzodiazepi[INVESTIGATOR_468036]  
- Periodically r eviewing state PDMP s to determine if patient is  filling p rescriptions or  
receiving opi[INVESTIGATOR_468037]  
- Using UDT  at least annually : UDTs are part of the opi[INVESTIGATOR_372462], which 
are now the standard of care for providers who prescribe opi[INVESTIGATOR_2438]. They are not part of 
the intervention . Some clinics ma y use point of care UDTs, others may choose clinical 
laboratory tests in which the results will not be available during the clinic visit in which 
the urine was obtained. This will be up to each clinic on how they choose to handle the 
UDTs.  
- Avoiding concurr ent opi[INVESTIGATOR_468038]  
- Offering treatment for opi[INVESTIGATOR_2427]  
6.2 SDM  Intervention  
SDM seeks to explore and compare treatment options, assess a patient’s values and preferences, and 
reach a shared decision between a patient and provider regarding current pain management options.  
SDM occurs when an SDM -trained provider and patient work together to make a health care decision 
that is best for the patient, which for this study is how to best manage pain with or without opi[INVESTIGATOR_2438]. The 
optimal d ecision considers evidence -based information about available health care options, the 
provider's knowledge and experience, and the patient's values and preferences. The best way to ensure 
that patients can make an informed decision about their care is for them to have sufficient information 
about the benefits and risks of their current opi[INVESTIGATOR_2512], other available treatment options, and 
appropriate use of opi[INVESTIGATOR_2438]. With SDM, patients are typi[INVESTIGATOR_468039], help patients feel better 
informed, are likely to promote more accurate expectations of benefits and harms, and most 
importantly to increase participation in decision making.  
The SDM intervention will have both provider and patient educational components. The content of the 
provider component will be based on the AHRQ SHARE Approach, which is a [ADDRESS_599669] to the patient.  The patient materials are based on  materials from 
AHRQ SHARE and the American Chronic Pain Association. The SDM Combined P atient Packet  used 
across the course of the 12-month  intervention period  is provided in the Appendix . Patient -specific 
benefits and harms of continued opi[INVESTIGATOR_468040]. Remote (e.g. p hone and telehealth) visits are 
also documented in the  EHR.  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Study Intervention  
Page 58 of 81 6.2.1 Enrollment Procedures for Arm 1  
Cross -reference: UNC IRBI S Application Section B.3.2.  
Arm [ADDRESS_599670] these visits. Patient visits may occur 
either in -person at the clinic or remotely using the clinic’s telehealth platform.  
The participant and provider will meet as often as needed  for pain management.  If the patient and 
physician decide that an opi[INVESTIGATOR_468041], the patient may have more frequent visits 
with the SDM provider.  A change in the frequency of visits due to medication changes is part of standard 
practice for opi[INVESTIGATOR_468042]. The patient may have  a total 
of 4 to 12 visits over an approxim ately 12-month  period.  (We expect about one or more visits every [ADDRESS_599671] more frequent follow -up visits to reinforce the provider -patient 
partnership, discuss potential withdrawal symptoms, such as temporary increase in pain, and assess 
pain and opi[INVESTIGATOR_468043] t based on clinical jud gement .) 
If participants are assigned to Arm 1 and their provider is trained in SDM, the participant will continue 
seeing this provider for the 12 -month intervention period. If the provider is not trained in SDM, 
participants will be asked to switch provid ers for opi[INVESTIGATOR_468044], and an SDM -trained provider 
will be assigned to the participant based on availability.  In the study’s consent form, participants are told 
about the potential need to change providers in order to receive opi[INVESTIGATOR_468045]  a trained 
provider.  Participants will continue with their current PCP or another provider not trained in SDM for 
their non -opi[INVESTIGATOR_207694] —such as for acute or chronic conditions —with an understanding that only a 
provider trained in SDM can manage participant s’ opi[INVESTIGATOR_207694].   
Distribution of Patient Materials for Arm [ADDRESS_599672] been randomized to Arm 1 of the 
study. The Research Coordinator will provide the SDM  Combined  Patient Packet  (see Appendix)  to the 
participant at the enrollment visit , electronically, or by [CONTACT_2319] . The SDM Patient Packet will include all the 
educational handouts (e.g., decision aids) so that participants who do not have Web access will have 
these documents. The packet w ill also contain links to Web -based versions of the materials for those 
who prefer to view the materials electronically. Participants will be strongly encouraged to review the 
suggested materials before each visit with the SDM provider.  
To provide some str ucture to the SDM intervention, we have asked clinicians to review one or more 
study aids at each SDM visit as appropriate. The structure is intended to have some flexib ility based on 
needs of the individual patient while providing guidance about content a nd order.  
6.2.2 Coordination of Care  
The SDM providers will document their opi[INVESTIGATOR_468046], which will facilitate communication between the participant’s SDM -trained and non -SDM –
trained providers.   
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Study Intervention  
Page 59 of 81 6.3 MI+CBT -CP Intervention  
Participants in Arm 2 will receive guideline -concordant pharmacotherapy, plus an empi[INVESTIGATOR_3675] -based 
behavioral pain management behavioral therapy intervention, including MI to enhance motivation for 
active participation in CBT -CP and for opi[INVESTIGATOR_2495] d dose reduction or cessation, and CBT -CP for pain --copi[INVESTIGATOR_468047].  The MI+CBT -CP intervention is an empi[INVESTIGATOR_468048].  MI and CBT -CP have  both  been used effectively with chronic pain.   
6.3.1 Enrollment  Procedures for Arm 2  
For Arm 2 participants, the GCC portion of the intervention will be delivered by [CONTACT_2299]’s primary 
care provider or pain specialist who is participating in the study and has been trained.  The participant 
will continue to see t he same provider for opi[INVESTIGATOR_468049] . Because Arm 2 participants  will not receive SDM decision aids, the providers will 
be trained not to use SDM with these patients (even if they have been tr ained in SDM) . 
Licensed clinicians, including masters - or PhD -level psychologists, licensed clinical social workers, or 
licensed professional counselors, will deliver the MI+CBT -CP intervention . To verify the training of 
MI+CBT -CP providers, RTI will reque st proof/documentation of fulfilling the study’s MI+CBT -CP training 
from each MI+CBT -CP provider. However, the MI/CBT -CP providers are clinical staff at their respective 
institutions and have experience with MI and CBT -CP. Thus, training will focus on the study MI/CBT -CP 
protocol, and not MI or CBT per se.  
The intervention will  include  1 individual MI session as soon as this session can be scheduled after 
enrollment and up to 8 CBT -CP group therapy sessions.  We anticipate the MI+CBT -CP component of the 
intervention may occur within [ADDRESS_599673] about 30 to  60 minutes , 
either in -person or via the clinic’s telehealth platform.   
MI is a style of interviewing, or a process, and because of this  it is difficult to formally “manualize.” 
(Indeed, it has generally been found to be less effective when manualized  [personal communication , 
Stephen Rollnick, PhD ].) Nevertheless, MI does have 4 processes:  engagement, focusing, evoking, and 
planning, as descr ibed in  Table [ADDRESS_599674] Manual (see Appendix) . The MI 
session can be conducted anytime between the baseline interview and Session [ADDRESS_599675] clinic procedures will be used for any follow -up. This 
is consistent with a pragmatic tria l and an ITT analysis.   
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599676] and mutually respectful working relationship  
c. Traps to avoid in the engagement phase:  
1. Assessment trap  
2. Expert trap  
3. Premature focus trap —i.e., don’t focus before engagement  
4. Labeling  
5. Blaming trap  
6. Labeling trap  
2. Focusing  
The focus is largely dictated by [CONTACT_468145] (REF: M and R) . 
Participants will enter the current study knowing that the purpose is to improve their functioning with 
chronic pain. A part of the effort to improve functioning  is a discussion on how opi[INVESTIGATOR_468050], their functioning, and other life goals —and the possibility of decreasing opi[INVESTIGATOR_2438]. 
Consequently , the initial focus will be on the patient’s chronic pain, well -being, their goals, barriers, and  
obstacles to their goals. One aspect of this will be a discussion on the role of opi[INVESTIGATOR_468051].  
3. Evoking  
The purpose is to strengthen motivation for change. Self -talk helps the patient express and resolve 
ambivalence. The patient expresses the pros and cons of available alternative strategies. In the case of 
opi[INVESTIGATOR_2438], the client would express what he or she sees as the advantages and disadvantages of decreasing 
opi[INVESTIGATOR_2438].  
4. Planning  
MI addresses people accordin g to their "level of change" (whether "precontemplative," 
"contemplative," or further along, such as in the "action" stage ). While some patients may enter the 
study with a desire to reduce opi[INVESTIGATOR_351170] , we anticipate that many will enter the study ambivalent 
about this. Regarding opi[INVESTIGATOR_40533], we anticipate that the patient could express a desire to  (1) maintain 
the current opi[INVESTIGATOR_40533], ( 2) decrease opi[INVESTIGATOR_468052], but continue to take opi[INVESTIGATOR_192845] a lower dose, 
(3) taper off opi[INVESTIGATOR_468053], or (4) increase opi[INVESTIGATOR_2438]. While some plans may be developed at the 
initial MI session, planning will generally evolve during the CBT -CP sessions, which will also involve 
elements of MI.  
 
Eight sessions of CBT -CP will be delivered in a group setting , in the  clinic or over the clinic’s telehealth 
platform . These sessions will focus on  
• education about chronic pain , 
• pacing and exercise , 
• relaxation techniques, including deep breathing and progressive muscle relaxation , 
• behavioral activation, including identification and scheduling of pleasurable activities , 
• cognitive restructuring, including the identification and challenging of maladaptive thoughts , 
and 
• behavioral sleep management training.  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599677] Manual , which is included in the Appendix . The MI-CBT-CP Session Guide and Handouts  for 
patients  are also in the Appendix . These will be provided in -person, electronically, or by [CONTACT_2319].  
While the primary focus of CBT -CP will be to improve physical functioning, education on opi[INVESTIGATOR_468054]. For example, we will include education on opi[INVESTIGATOR_468055] (e.g., that 
opi[INVESTIGATOR_468056]) and opi[INVESTIGATOR_27293]. In the cognitive restructuring 
component, we will discuss common catastrophizing thoughts about medication (e.g., “I don’t know 
what else to do for this pain other than take op ioids”).  
The provider  will document the intervention delivery in the EHR.  
6.3.[ADDRESS_599678] will inform the primar y provider, with the participant’s permission. 
The communication linkage between the therapi[INVESTIGATOR_468057].  
To facilitate this linkage, f ollowing  MI+CBT -CP group sessions, we will ask Arm 2 participants  to self -
report their perceptions of: the helpfulness of the CBT group sessions; the quality of their current 
approach to pain management; their ability to manage pain; and their goal with their opi[INVESTIGATOR_40533]. The 
purpose of the form is to facilitate coordin ation of care. The information will only be used for clinical 
purposes and will not be used fo r data analysis.  
This will be done via  a form, the Post -CBT Group Session Form  (see Appendix). The form is voluntary,  
and patients may skip any question they do n ot wish to answer. This form was developed with the input 
of patient representatives, primary care physicians, therapi[INVESTIGATOR_11437], and the research team.  
The form will ask the participant if their responses can be shared with their health care provider. If the 
patient says yes, the therapi[INVESTIGATOR_468058] .  
The form will be administered on paper if the CBT session is conducted in -person, and by [CONTACT_468146].  
The inter -provider messaging system within the Epic EHR system will be the primary means of 
communicating the participant’s motivation to decrease opi[INVESTIGATOR_2438].  
We have work ed with our clinical sites to solicit provider input to determine what is customary and 
feasible for this pragmatic trial. Means of communication may include co pying the primary provider on 
the therapy note, sending information via secure email, requesting read receipts, requiring a response 
from the provider acknowledging they have read the note, and/or including the provider’s nurse on the 
messages .
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Study Intervention Training and Documentation  
Page 62 of 81 7 STUDY INTER VENTION TRAINING AND DOCUMENTATION  
Cross -reference: UNC IRBIS Application section A.4.7.  
7.[ADDRESS_599679].  To document provider s’ qualifications to provide GCC, the 
study team will ask each study provider  to (1) affirm documentation of state -level Continuing Medical 
Education (CME) training for opi[INVESTIGATOR_468059] (2) complete study -specific 
training with the CDC guideline training modules.  
7.[ADDRESS_599680] to the patient , as shown in  Table  10. 
Table  10. SHARE Approach to Shared Decision Making  
Review essential steps of shared decision making:  
Step 1: Seek your pat ient’s participation.  
Step 2: Help your patient explore and compare treatment options.  
Step 3: Assess your patient’s values and preferences.  
Step 4: Reach a decision with your patient.  
Step 5: Evaluate your patient’s decision.  
7.3 MI+CBT -CP Provider  Training  
The study team will identify one to four provider s to provide the MI+CBT -CP intervention. Only 
provider s who have completed the study -specific MI+CBT -CP training will be able to deliver the MI+CBT -
CP intervention. The training process will be based on Motivational Interviewing  by [CONTACT_468147]: A Cognitive Behavioral Therapy Approach Therapi[INVESTIGATOR_26051] .,85 
7.4 Research Coordinator T raining  
All Research Coordinators will complete a study training prior to beginning of recruitment  to review all 
elements of the protocol and their specific responsibilities.  
 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Safety Management  
Page 63 of 81 8 SAFETY MANAGEMENT  
8.1 Potential for Risk  
8.1.1 Potential Psychological Risks  
Cross -reference: UNC IRBIS Application section A.6.1, A.6.2.  
There is a risk that some of the survey questions or intervention content could result in a participant 
feeling some emotional distress or embarrassment. The participant may refuse to answer the questions 
and may stop participation in this study at any time. A safety protocol (suicide prevention plan) will be 
activated in very rare instances in which a participant is feeling severe or life -threatening distress. 
Protocol Section 3.3, Screening, des cribes the procedures we will use to minimize these risks.  
The chance of a breach of confidentiality is rare. There is a very small risk that someone could get access 
to study information we have stored about participants and may misuse it. Confidentialit y is very 
important to us. We will take several steps to protect it, such as training staff, using secure databases, 
de-identifying data, collecting only the minimum amount of information necessary, and limiting access 
to the information. RTI will apply fo r a Certificate of Confidentiality from NIH. Research staff who have 
direct contact [CONTACT_468148].  Other 
measures we are taking to mitigate risks to subjects’ privacy and confidentiality are d escribed in section 
9.3, Protecting Confidentiality .  
8.1.2 Potential Social Risks  
Cross -reference: UNC IRBIS Application section A.6.3, A.6.4.  
No potential social risks have been identified.  
8.1.3 Potential Economic Risks  
Cross -reference: UNC IRBIS Application sectio ns A.6.5, A.6.6 (risks) , B.5.1  (costs) . 
If the participant is randomized to the CBT arm, a co -pay may be required for each CBT session 
attended.  
If the participant is randomized to the SDM arm, and if the participant changes opi[INVESTIGATOR_40533], there may 
be additional visits. These visits are part of the standard of care for opi[INVESTIGATOR_8560]. Clinical sites 
(Duke, UNC, VUMC) will work with clinic managem ent to tailor delivery of the SDM intervention based 
on needs of their clinic. For example, one site may choose to enroll only the patients seen by [CONTACT_468149] -
trained providers whereas another site may have the patient switch all care to an SDM -trained clinician.   
Thus, clinics can do one or more of the following if they deliver the intervention as outlined in the 
protocol:  
• Enroll patients from only SDM -trained providers  
• Adhere to clinic guidelines that use dual management of pain patients (which is currently in p lace in 
some of the clinics)  
• Have SDM providers provide primary care as well  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Safety Management  
Page 64 of 81 We will be fully transparent with the potential respondents when we explain the study to them, that 
they will be responsible for additional co -pays that may be incurred as part of the research.  
8.1.4 Potential Legal Risks  
Cross -reference: UNC IRBIS Application section A.6.7, A.6.8.  
The study will collect information about alcohol/substance abuse and misuse via the subject’s electronic 
medical record data, as measured by [CONTACT_48334] -9/[ADDRESS_599681] will not be asked about these topi[INVESTIGATOR_468060] -report surveys.  
The major legal risk to subjects would come from a breach of privacy & confidentiality. To mitigate this 
risk, the EHR data will be de -identified and will use a study identifie r instead of patient identifiers. We 
will have data use agreements in place to share the data across institutions. Other measures we are 
taking to mitigate risks to subjects’ privacy and confidentiality are described in section 9.3, Protecting 
Confidential ity.  
8.1.5 Potential Physical Risks  
Cross -reference: UNC IRBIS Application section A.6.9, A.6.10.  
There is some potential risk that participants may experience increased pain if they reduce or 
discontinue their opi[INVESTIGATOR_2536].  
We expect any side effects to be rare or infrequent and mild -to-moderate.  
This study is comparing two different behavioral interventions for patients with chronic pain who are 
already on chronic opi[INVESTIGATOR_2538]. Some of the intervention content is about tapering or discontinuing 
opi[INVESTIGATOR_27968]. The participant may choose to request to taper or discontinue opi[INVESTIGATOR_2438]. Lowering the dose of 
opi[INVESTIGATOR_468061]. But, there are no extra risks from this study 
compared to discontinuation as part of usual care.  
The approach of this trial is to promote a controlled opi[INVESTIGATOR_187481], which in some cases might lead to 
complete discontinuation, with a patient’s consent . The protocol does not specify or foresee abrupt 
tapering.  
If patients do choose to taper, the physici ans will be doing a very gradual taper of their opi[INVESTIGATOR_2438] (as per 
CDC guidelines, 10% per week), which has rare to infrequent risk of withdrawal. If withdrawal is 
experienced, mild to moderate symptoms are expected. These symptoms may include low energy; 
irritability; anxiety; agitation; insomnia; sweats; muscle aches and pain; as well as abdominal crampi[INVESTIGATOR_007], 
nausea,  and vomiting. Patients will be advised to call their provider if they experience symptoms of 
withdrawal.  
To reduce physiological risk, certain s afeguards will be implemented at RTI and at all clinical institutions. 
Procedures to reduce clinical risk include intensive medical monitoring of AEs and medical management 
common for this study population.  
 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599682] developed a plan for protecting human subjects, beginning with obtaining IRB approval. The 3 
clinical institutions that are part of the PCORnet STAR CRN —UNC, Duke, and VUMC —have taken steps 
to enter into a reliance agreement to utilize a  single IRB at UNC to review this project.  
Assurances that the benefits of study participation outweigh the risk are made through informed 
consent procedures, maintenance of participant confidentiality, adherence to HIPAA regulations, and 
close monitoring and reporting of AEs. All research staff who will assist with this pragmatic trial (i.e., 
those who contribute to the scientific development or execution of the study in a substantive, 
measurable way) will complete the appropriate Collaborative Institution al Training Initiative (CITI) 
modules , so that they are aware of requirements for protection of human subjects. Each of the 
participating institutions and RTI holds a Federal -Wide Assurance (FWA) for the Protection of Human 
Subjects, which ensures that the  institution’s human research activities comply with the requirements 
set forth in 45 CFR 46. In addition to the federal regulations, RTI will take into consideration any state or 
local laws regarding human subjects that may be more protective than the fed eral statutes.  
All the institutional IRBs will monitor the research process at their respective practice under the SMART 
/single IRB arrangement noted above to ensure that the procedures for protecting human subject rights 
are followed by [CONTACT_468150]. RTI and the participating institutions will maintain all records of initial and 
annual approvals.  
8.2.[ADDRESS_599683]  
Cross -reference: UNC IRBIS Application A.7.2.  
The study has a DSMB that consists of individuals who are not participating investigators in this trial. The 
primary responsibility of the DSMB is to review cumulative study data to evaluate safety, study conduct, 
scientific validity, and data integrity to ensure that the study is operating in a safe and ethical manner. 
The DSMB will meet [ADDRESS_599684] of the trial. The RTI Coordinating Center will prepare and submit reports to  the 
DSMB. The report will include all AE data reported in REDCap (available from the PCORnet CDM data 
extraction or provided by [CONTACT_6270] -report during participant surveys) and will be summarized by [CONTACT_468151].  
8.2.3 Data and Safety Monitoring Plan  
Cross -reference: UNC IRBIS Application A.7.2 , C.1.1 .  
The study team has developed and finalized a DSMP. This plan will adhere to the PCORI guidelines on 
DSMPs.  
8.3 Adverse Event/Serious Adverse Event monitoring and reporting procedures  
An AE is any untoward or unfavorable medical occurrence in a human subject, including any abnormal 
sign (for example, abnormal physical exam or laboratory finding), symptom, or disease temporally 
associated with the subject’s parti cipation in the research, whether or not considered related to the 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599685]’s participation in the research (modified from the definition of AEs in the 1996 International 
Conference on Harmonization E -6 Guidelines for Good Clinical Practice).  
An SAE is an AE that meets any one of the following criteria: results in death, is life threatening, or 
requires inpatient hospi[INVESTIGATOR_312], results in persistent 
or significant disability/incapacity, birth  defects or based on medical judgement may jeopardize the 
participants health or may require medical or surgical intervention. This study does not involve an 
investigational product , device intervention, or highly invasive data collection procedure. Howeve r, 
recognizing that unanticipated events (see below) can occur during any study, the following reporting 
protocols will apply . 
Study participation and exposure to the interventions are expected to have a moderately low risk of AEs 
for participants , in the form of adverse effects associated with reduction of opi[INVESTIGATOR_375324] . At the same 
time, the underlying chronic conditions of the participants may naturally lead to deleterious health 
outcomes. To efficiently collect safety information that is relevant to stu dy participation and the 
interventions, detailed information concerning a prespecified set of AEs and SAEs will be collected and 
evaluated throughout the conduct of the trial.  
8.3.1 Reportable Adverse Events and Serious Adverse Events  
For the purposes of this s tudy, an event will be considered reportable (collected for data entry)  if it 
meets at  least one of the criteria below. The AEs and SAEs shown in Table  [ADDRESS_599686] will not be recorded or reported.  
Table  11. Reportable Events and Assessment Methods  
Reportable Event  Assessment Method  
Suicide risk (active suicidal ideation or attempted suicide)  
(see section 8.3.5  below)  Adverse Event Case Report Form  
All Deaths ( including  opi[INVESTIGATOR_2480] -related , suicide, and all other 
deaths ) Adverse Event Case Report Form, PCORnet EHR -
based data, National Death Index (available after 
study completion) , publicly available data   
Hospi[INVESTIGATOR_468062] (ED) visits 
related to opi[INVESTIGATOR_2441] (overdose or withdrawal) or related 
to suicide attempt  Advers e Event Case Report Form, PCORnet EHR -
based data, patient self -report via 6 - and 12 -month  
follow -up surveys  
 
 
When one of these AEs is identified, the institution PI [INVESTIGATOR_468063]:  
• Unanticipated  (i.e., unexpected ). These  events are AEs that are new or greater than previously 
known, in terms of nature, severity, frequency or occurrence, as documented in the protocol, 
consent, or other study documents approved by [CONTACT_1201] (OHRP - 
https://www.hhs.gov/ohrp/regulations -and-policy/guidance/reviewing -unanticipated -
problems/index.html ). 
• Related  (possibly related, probably related, or definitely relat ed) to study participation . 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599687] be followed when an SAE meets both of these conditions:  
• SAE is considered unanticipated /unexpected , AND  
• at a minimum, possibly related  to study participation . 
Institutions must  report expedited SAEs within 2 business days of the Institut ion’s awareness to the 
single UNC IRB and to RTI.  RTI must notify DSMB of the event within [ADDRESS_599688] provide a 
summary report of the event to DSMB within 7 days.  
8.3.3 Periodic (Non -Expedited) Reporting  
Periodic (Non -Expedited) reporting procedures mus t be followed when the SAE meets both of these 
conditions:  
• SAE is considered unanticipated/unexpected OR expected AND  
• SAE is NOT related to study participation.  
RTI must provide a summary report of the event to DSMB at the next DSMB meeting as part of the 
regular DSMB meeting report.  
8.3.[ADDRESS_599689] and report unanticipated (i.e., unexpected) problems that may involve risk to the 
participant or study staff, but do not necessarily result in an AE (i.e., harm). An example of an 
unanticipated problem that may not result in an AE is misplacement of a participant’s research record 
containing PII such that the risk of loss of confidentiality is introduced. This event is reportable 
regardless of whether the confidentiality is breac hed or not breached.   
Institutions must report o ther unanticipated problems that are not SAEs but involve substantial harm (or 
genuine risk of substantive harm) to the safety, rights, or welfare of the institution’s research 
participants, research staff, o r others to the single UNC IRB  and RTI within 5 business days . 
Otherwise, the institution will report unanticipated problems to the single IRB and RTI on an annual 
basis at the time of continuing review.  
8.3.5 Suicidality  
We will capture suicide risk (active su icidal ideation or attempted suicide) during the intervention period 
during clinical encounters. As this is a pragmatic unmasked behavioral intervention trial, suicide risk will 
only be captured if the participant  indicates intent to self -harm during the c linical intervention visit; the 
provider  will not conduct a study -specific suicide risk assessment. If th e clinic becomes aware of suicide 
ideation, the provider  will follow the institution’s or clinic’s protocols , as described in our  Safety 
Protocol  (see Appendix) . Similarly, if active suicide ideation is self -reported to the research coordinator 
during the screening visit review of exclusion criteria, the provider  will be notified and will follow the 
institution’s or clinic’s protocols.  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Safety Management  
Page 68 of 81 The therapi[INVESTIGATOR_468064] +CBT -CP intervention will all be masters - or PhD -level mental health 
provider s with training and experience handling suicidal patients. If a participant  does express suicidal 
ideation, the therapi[INVESTIGATOR_468065]. Similarly, if a 
participant  being seen in the SDM  intervention (Arm 1) expresses suicidal ideation, the clinic will handle 
it in the man ner that they would in their clinical practice.   
The provider  will report the event to the institution’s Research Coordinator, and the Research 
Coordinator will complete an Adverse Event Case Report Form . 
We will capture whether the participant  has been to the ED or had an inpatient hospi[INVESTIGATOR_468066]-harm via self -report and PCORNet CDM data extraction. We will capture information on when 
and where this occurred.  
8.3.6 Deaths  
If site study staff bec ome aware of the death of a participant, the site will report the event via the 
adverse event case report form. We will include  the cause of death  in the report . If the cause of death is 
unknown and not available in the EHR,  the study’s DSMB has requested that the study try to obtain 
cause of death information from the participant’s death certificate.  The DSMB will use the information 
to make an objective decision about whether the death was possibly related to the study.   
Study staff at the enrolling site will request a copy of the death certificate from the appropriate state 
agency , if such information is publicly available . Whether death certificates are available publicly 
depends on the state. The NC Department of Health and Human Services  makes available uncertified 
copi[INVESTIGATOR_468067], unless legal 
restrictions apply. Study staff will abide by [CONTACT_468152] . When r equest ing death certificates , study staff will not disclose  any information linking the 
decedent to their participation in the INSPI[INVESTIGATOR_208847].   
 
Once the death certificate is obtained, the site will provide the cause of death information  to RTI via the 
adverse event cas e report form . RTI will then use this information to update Serious Adverse Event (SAE) 
reports that are provided to the DSMB.   
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Data Management  
Page 69 of 81 9 DATA MANAGEMENT  
Cross -reference: UNC IRBIS Application Section A.8.4.  
9.[ADDRESS_599690] eligibility inclusion and exclusion criteria will be determined from data recorded in the in stitution’s 
EHR. Institution informatics staff will use specified criteria to develop an EHR recruitment phenotype 
report, in the form of a file that lists patients names, demographics, provider names, and key selected 
criteria for patients who meet this i nitial screening criteria. This file will be produced by [CONTACT_468153] a secure study folder on a HIPAA -compliant server, with access 
restricted to study staff. Prior to study startup, the study team will validate t he phenotype and make any 
adjustments as needed.  
All details of participant screening and recruitment will be tracked by [CONTACT_468154] a Pre -
Screening Database stored in a secured electronic environment within each clinical institution.  
To facilitate remote enrollment, we will use electronic versions of the enrollment forms (Consent to 
Screen, the Study Consent, the HIPAA Authorization, and the Participant Contact [CONTACT_7171]) in a 
REDCap database stored securely at each clinical institution . These REDCap databases will be separate 
from the central REDCap study database stored at RTI because they will contain PII. Electronic signatures 
will be captured using REDCap’s Consent module.  REDCap will generate and store a signed version of the 
conse nt form as a PDF. The participant will have the option to download a copy of their signed consent 
form.  
Summary/aggregate screening data (such as counts) will be reported by [CONTACT_468155] a central REDCap study d atabase accessible by [CONTACT_468156].  
9.2 Enrolled Participant Data Management  
We will use REDCap86 as our core data capture system and repository for the aggregation of participant 
screening, r ecruitment, enrollment, tracking, and baseline self-reported outcome data .  
REDCap  is a secure (Health Insurance Portability and Accountability Act of 1996 [HIPAA], 21 Code of 
Federal Regulations [CFR] Part 11), and Federal Information Security Management Act (FISMA) -
compliant web application designed to facilitate participant enrollmen t, randomization, tracking, and 
multiple modes of data entry.  
For consented participants, baseline monitoring and screening information will be entered into the 
central REDCap study database  stored at RTI , and eligible participants will be randomized direc tly in 
REDCap. Collection of patient -reported outcomes at baseline will be performed using REDCap’s web -
based survey tools. Should some participants find the tablet challenging, paper forms will be available. 
Subject status and adverse events will also be recorded in the REDCap Study database.  
 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599691] the 6 - (T2) and 12 -month (T3) follow -up surveys using a combination of Voxco for 
survey data collection (via web and CATI) and the RTI’s in -house survey managem ent system (Nirvana) 
system for case management. Follow -up data collection will be scheduled automatically at the 
appropriate assessment time from the participant’s randomization date.  
Voxco  is an integrated interviewing and case management system that pr ovides state -of-the-art tools 
for conducting telephone survey research. The Voxco system runs in RTI’s Federal Information 
Processing Standards ( FIPS) moderate network, providing a secure data collection environment for data 
collection projects.  
RTI’s in -house survey management system, Nirvana , is a control and case management system for 
multimodal survey projects and runs in RTI’s  FIPS moderate network .  
9.[ADDRESS_599692] qualitative data using a web conferencing platform (for example,  Zoom  or 
BlueJeans ). We will take security measures including:  
• Using a unique, automatically generated meeting ID  
• Requiring a password for the meeting  
• Using the “virtual waiting room” to approve meeting participants before entering  
• Locking the meeting after it has started  
• Preventing participants from screen sharing  
 
RTI staff will consult with the RTI Privacy Officer to make sure that the platform used adheres to 
institution requirements.  
9.[ADDRESS_599693] embedded quality control measures such as reports on 
missing data fields and range -checks on data fields where applicable. Additional reports may be 
developed to check cross -form and cross -data sour ce consistencies. These reports facilitate timely 
identification and resolution of problems in data collection and processing . 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Confidentiality of the Data  
Page 71 of 81 10 CONFIDENTIALITY  OF THE DATA  
10.1 Procedures for Maintaining Confidentiality  
Cross -reference: UNC IRBIS Application A.10.1 , A.11.2 , B.1. 8, B.3.6 (privacy procedures)  
As with any research, the potential exists for a breach in confidentiality ; however, this is very unlikely.  
Study sites will establish and maintain the appropriate administrative, technical, and physical safeguards 
to protect the confidentialit y of the data and to prevent unauthorized use or access to the data. The 
study will not disclose data nor permit others to use the data except as described in this protocol.  
Access to hard copy or electronic data is restricted to authorized staff members.  
 
To maintain confidentiality during enrollment:  
• During in -person enrollment , survey data will be  collect ed in a private location , which  reduces 
the risk that answers to interview questions will be overheard by [CONTACT_468157].  
• Similarly, during remote enrollment, the RC will ask the patient to complete screening and 
enrollment in a private location.  
• Information obtained through these processes will not be disclosed to anyone who is not 
directly involved in the study, except in cases where potentially life -threatening conditions are 
revealed.  
To maintain confidentiality during group intervention sessions:  
• Participant s will be told that all information shared during the session is private and should not 
be shared with anyone outside the group session.  
• The therapi[INVESTIGATOR_468068] a Patient Encounter 
note within the EHR to be used as an indicator of adherence with the study intervention .  
• Because the post -CBT group session form is only used for clinical purposes, it is not linked to the 
participant ID. Participants will be asked to complete the form in a private location and return it 
at their next session in an envelope, in order to reduce the risk that their responses will be seen 
by [CONTACT_2312]. After the therapi[INVESTIGATOR_468069], he/she will destroy the hard copy 
form as per institution policy.  
To maintain con fidentiality of the data:  
• To ensure consistent data linking across all clinical institutions, the PCORnet data warehouse 
uses a global unique identifier (GUID) to uniquely identify a patient’s EHR data. A GUID is a long, 
unique, alphanumeric identifier ge nerated by [CONTACT_468158][INVESTIGATOR_468070]’s medical record. Use of a GUID facilitates the unique 
identification of each patient, without the need to transmit PHI or PII.  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Confidentiality of the Data  
Page 72 of 81 • Identifiers will be stored separately  from the research data. Research data will be coded with a 
study -specific participant identifier. The linkage file between the participant ID and PII will be 
stored in a different file location maintained by [CONTACT_468159].  
• The participant ID wi ll be used to link research data across data collection sources and the 
study’s REDCap, Voxco, and Nirvana data capture systems.  
• All transfers of EHR data from each clinical institution’s PCORnet data warehouse to the RTI Data 
Coordinating Center will be limited to protocol -specified data elements for randomized study 
subjects and will be identified only by [CONTACT_468160].  
To maintain confidentiality during qualitative research activities:  
• Participants will be told that all information shared during the session is private and should not 
be shared with anyone outside the group session.  
• We will use a secure web conferencing platform  and adhere to RTI requirements for use of web 
conferencing with research studies.  
• We will only record audio and not video. We will also tell participants not  to record the session 
or take screenshots.  
• Audio recordings will  be stored on secure, e ncrypted computers. They will  only be used to 
create transcripts.  
• Qualitative data will not be connected with the participant’s main study participant ID.  
• Participant responses will be coded with a separate identifier for the qualitative research 
compone nt. The linkage file between the qualitative ID and PII will be stored in a different , 
secure file location maintained by [CONTACT_468161] .  
• Transcripts will not contain PII.  
• Qualitative data will not be shared with site research staff or health care providers.  
10.1.1  Certificate of Confidentiality  
Cross -reference: UNC IRBIS Application A.10.4, B.3.[ADDRESS_599694] the privacy of study participants, a Certificate of Confidentiality will be issued by [CONTACT_4878] (NIH).  This certificate protects identifiable research information from 
forced disclosure. It allows the investigator and others who have access to research records to refuse to 
disclose identifying information on research participation in any civil, criminal, adminis trative, legislative, 
or other proceeding, whether at the federal, state, or local level. By [CONTACT_261912], 
Certificates of Confidentiality hel p achieve the research objectives and promote participation in studies 
by [CONTACT_4205][INVESTIGATOR_21783].  
10.2 Procedures for Data Transmission  
Cross -reference: UNC IRBIS Application section A.10.2 , A.11.1, A.11.2 , C.1.2, C.1.3 , C.2.1 (DUAs)  
Data Use Agreements (DUAs) will be completed between RTI and each study site prior to the transfer of 
any data if required by [CONTACT_8236].  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/[ADDRESS_599695] the specified data elements into a study -specific 
DataMart extraction, which after validation at the institutions, will be transferred to the RTI Data 
Coordinating Center at prespecified times during the study.  
The E HR data extracted from each study site’s CDM will be uploaded to the RTI Data Coordinating 
Center via a HTTP Secure File Transfer Protocol (SFTP) setup by [CONTACT_142861]. SFTP provides a high level of security 
(SSL Encryption) and allows sites to transfer files via a  web browser. Each site will only have connection 
to their own sites’ SFTP folder, which is accessed via a username [CONTACT_2383]. These credentials will 
only be provided to each site’s Project Manager and CDM programmer. The EHR data will be housed on 
the FIPS Low server at RTI because they will not contain PHI/PII.  
10.2.[ADDRESS_599696] information (as described on page 37) to RTI 
International so that RTI can conduct the T2 and T3 follow -up surveys. Only contact [CONTACT_468162].  
A separate SFTP will be setup to transfer the participant contact [CONTACT_468163] -up surveys. Because these data contain PHI/PII, they will be 
housed on a FIPS Moderate server at RTI that meets FIPS -199 requirements for PII, including Risk/Impact 
Levels of confidentiality (moderate), integrity (moderate), and avail ability (low).  
10.3 Collection of Sensitive Information  
Cross -reference : UNC IRBIS application A.10.3.  
The research data collected from the EHR will include the following information that some individuals 
may consider sensitive:  
• Mental health disorders, defi ned by [CONTACT_48334] -10 codes (e.g., depression, anxiety, schizophrenia, 
bipolar disorder, suicide attempt/intent)  
• Alcohol/substance misuse or abuse as measured by [CONTACT_48334] -[ADDRESS_599697] -study disposition of identifiable data  
Cross -reference: UNC IRBIS application A.12.1  
At the end of the study, a de -identified public -use study database will be delivered to PCORI. The 
de-identified database will be limited to the items specified in Section 4 (Study Evaluations and 
Measurements) and will not include any participant identifying information, such as dates, text fields, 
extremely rare and potentially identifying events, or other potentially identifying data.  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
Plans for Publication  
Page 74 of 81 11 PLANS FOR PUBLICATION  
We plan to disseminate the study findings via conference presentations and peer -reviewed publications 
in professional journals.  Any study findings that are reported in professional journals or at meetings will 
not contain any PII  or PHI . The study leadership team w ill develop a publication policy for the study . No 
patient identifying information will be included in any disseminated products.  
 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
References  
Page 75 of 81 12 REFERENCES  
1. Verhaak PF, Kerssens JJ, Dekker J, Sorbi MJ, Bensing JM. Prevalence of chronic benign pain 
disorder among adults: A review of the literature. Pain. 1998;77:231 -239.  
2. Institute of Medicine of the National Academies. Relieving pain in America: a blueprint for 
transforming prevention, care, education, and research.  June 29 2011.  
3. Stang P, Von Korff M, Galer BS. Reduced labor force participation among primary care patients 
with headache. J Abnorm Child Psychol. 1998;13(5):[ADDRESS_599698] P. The economic costs of pain in the [LOCATION_002]. The journal of pain : 
official journal of the American Pain Society. 2012;13(8):715 -724. 
doi:10.1016/j.jpain.2012.03.009  
5. Gureje O, Von Korff M, Kola L, et al. The relation between multiple pains and menta l disorders: 
Results from the World Mental Health Surveys. Pain. 2008;135:[ADDRESS_599699], Cox BJ. Depression and anxiety associated with three pain 
conditions: results from a nationally representative sample. Pain. 2004;111(1 -2):77 -83. 
doi:10.1016/j.pain.2004.06.[ADDRESS_599700] M, et al. Chronic spi[INVESTIGATOR_272926] -mental comorbidity in the 
[LOCATION_002]: Results from the National Comorbidity Survey Replication. Pain. 2005;113:331 -
339.  
8. Saree n J, Jacobi F, Cox BJ, Belik SL, Clara I, Stein MB. Disability and poor quality of life associated 
with comorbid anxiety disorders and physical conditions. Arch Intern Med. 2006;166(19):2109 -
2116. doi:10.1001/archinte.166.19.[ADDRESS_599701]. Exp laining high rates of depression in chronic pain: A diathesis -stress 
framework. Psychol Bull. 1996;119(1):95 -110. doi: 10.1037/0033 -2909.119.1.95  
10. Gureje O, Simon GE, Von Korff M. A cross -national study of the course of persistent pain in 
primary care. Pain. 2001;92(1 -2):195 -200.  
11. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Trends in use of 
opi[INVESTIGATOR_378551] -cancer pain conditions 2000 -2005 in commercial and Medicaid insurance plans: 
the TROUP study. Pain. 2008;138(2):440 -449. doi:10.1016/j.pain.2008.04.027  
12. Caudill -Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for 
musculoskeletal pain in US: 1980 vs. 2000. Pain. 2004;109(3):514 -519.  
13. Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessm ent of trends in the medical use and 
abuse of opi[INVESTIGATOR_468071]: 1997 -2002. J Pain Symptom 
Manage. 2004;28(2):176 -188. doi:10.1016/j.jpainsymman.2004.01.003  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
References  
Page 76 of 81 14. Zacny J, Bigelow G, Compton P, Foley K, Iguchi M, Sanner ud C. College on Problems of Drug 
Dependence taskforce on prescription opi[INVESTIGATOR_411048] -medical use and abuse: Position statement. 
Drug Alcohol Depend. 2003;69:215 -232.  
15. Food and Drug Administration. FDA to Meet with Drug Companies about REMS for Certain 
Opio id Drugs. Food and Drug Administration, website. 
http://www.fda.gov/Drugs/DrugSafety/Informationby[CONTACT_468164]/ucm163647.htm . Published 
2009. Accessed October 02, 2009.  
16. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opi[INVESTIGATOR_281582] --[LOCATION_002], 1999 -2008. MMWR.  2011;60(43):1487 -1492.  
17. Edlund MJ, Martin BC, DeVries A, Fan MY, Braden JB, Sul livan MD. Trends in use of opi[INVESTIGATOR_468072] -cancer pain among individuals with mental health and substance disorders:  the 
TROUP study. Clin J Pain. 2010;Jan;26(1):1 -8. 
18. IQVIA. Prescription opi[INVESTIGATOR_468073] U.S. has declined by 60% from 2011 pea k, according to new 
report from the IQVIA ™ Institute for Human Data Science. Business Wire website. 
https://www.iqvia.com/newsroom/2020/12/prescription -opi[INVESTIGATOR_2480] -use-in-the-us-has-declined -by-
60-from -2011 -peak -according -to-new -report -from -the. Published December 17, 2020. Accessed 
December 27, 2020.  
19. Levy B, Paulozzi L, Mack KA, Jones CM. Trends in Opi[INVESTIGATOR_380530] -Prescribing Rates by [CONTACT_380594], 
U.S., 2007 -2012. Am J Prev Med. 2015;49(3):409 -413. doi:10.1016/j.amepre.2015.02.020  
20. Martin BC, Fan MY, Edlund MJ, Devries A, Braden JB, Sullivan MD. Long -term chronic opi[INVESTIGATOR_468074]. J Gen Intern Med. 2011;26(12):1450 -1457. 
doi:10.1007/s11606 -011-1771 -0 
21. Vanderlip ER, Sullivan MD, Edlund MJ, et al. National study of discontinuation of long -term 
opi[INVESTIGATOR_468075]. Pain.  2014;155(12):2673 -2679. doi:10.1016/j.pain.2014.09.034  
22. Kaiser Family Foundation. Opi[INVESTIGATOR_468076]. Kaiser Family Foundation website. 
http://kff.org/other/state -indicator/opi[INVESTIGATOR_2480] -overdose -deaths -by-
gender/?dataView=1&currentTimeframe=0 . Published 2014.  
23. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical 
overdose fatalities. Jama. 2008;300(22):2613 -2620. doi:10.1001/jama.2008.802  
24. Bohnert ASB, Valenstein M, Bair MJ, et al. Association Between Opi[INVESTIGATOR_468077] -Related Deaths. Jama -J Am Med Assoc. 2011;305(13):1315 -1321. 
doi:10.1001/jama.2011.370  
25. Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of 
prescription opi[INVESTIGATOR_2554], dependence, and misuse in the [LOCATION_002]. Pain Med. 
2011;12(4):657 -667. doi:10.1111/j.1526 -4637.2011.[ZIP_CODE].x  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
References  
Page 77 of 81 26. National Survey on Drug Use and Health. SAMHSA's Latest National Survey on Drug Use & 
Health. Substance Abuse and Mental Health Services Administration website. 
http://oas.samhsa.gov/NSDUHLatest.htm . Published 2010. Updated: September 16. Accessed 
Feb 7, 2009.  
27. NIDA. Nationwide Trends. website. 
https://www.drugabuse.gov/publications/drugfacts/nationwide -trends . Published 2015. 
Updated: June 25, 2015. Accessed October 16, 2019.  
28. Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opi[INVESTIGATOR_187496] - United 
States, 2016. MMWR Recomm Rep. 2016;65(1):1 -49. doi:10.[ZIP_CODE]/mmwr.rr6501e1  
29. North Carolina Medical Board. Policy for the use of opi[INVESTIGATOR_468078]. 
http://www.ncmedboard.org/image s/uploads/other_pdfs/Policy_for_the_Use_of_Opi[INVESTIGATOR_858]_for_
the_Treatment_of_Pain_June_4_2014.pdf . Accessed October 25, 2017.  
30. Department of Veterans Affairs and Department of Defense. VA/DoD Clinical Practice Guideline 
for Management of Opi[INVESTIGATOR_468079]. 
https://www.va.gov/painmanagement/docs/cpg_opi[INVESTIGATOR_285736]_summary.pdf . Published 2010.  
31. Washington State Agency Medical Directors' Group. Interagency guideline on opi[INVESTIGATOR_468080] -cancer pain (CNCP): 2010 update. 
http://www.agencymeddirectors.wa.gov/files /opi[INVESTIGATOR_468081].pdf . Published 2010.  
32. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opi[INVESTIGATOR_468082]. The journal of pain : official journal of the American Pa in Society. 
2009;10(2):113 -130. doi:10.1016/j.jpain.2008.10.[ADDRESS_599702] Psychiatr Care. 
2015;51(3):2 11-219. doi:10.1111/ppc.[ZIP_CODE]  
34. McDonald DC, Carlson K, Izrael D. Geographic variation in opi[INVESTIGATOR_468083] U.S. The 
journal of pain : official journal of the American Pain Society. 2012;13(10):988 -996. 
doi:10.1016/j.jpain.2012.07.007  
35. Centers  for Disease Control and Prevention. Injury Prevention & Control: Prescription Drug 
Overdose. Drug Overdose Deaths by [CONTACT_180347], US 2013 and 2014. Centers for Disease Control and 
Prevention website. http://www.cdc.gov/drugoverdose/data/statedeaths.html . Published 2015. 
Updated: December 18. Accessed January 28, 2016.  
36. National Institutes of Health Interagency Pain Research Coordinating Committee. National P ain 
Strategy. http://iprcc.nih.gov/National_Pain_Strategy/NPS_Main.htm . Published 2015.  
37. National Institutes of Health. Pathways to Prevention Wo rkshop: The Role of Opi[INVESTIGATOR_468084] 29 -30 2014.  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
References  
Page 78 of 81 38. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen 
Intern Med. 2012;27(10):1361 -1367. doi:10.1007/s11606 -012-2077 -6 
39. Barry MJ, Edgman -Levitan S. Shared decision making --pi[INVESTIGATOR_27308] -centered care. N Engl J 
Med. 2012;366(9):780 -781. doi:10.1056/NEJMp1109283  
40. Mayo Clinic. Mayo Clinic Shared Decision Making National Resource Center. Mayo Clinic 
website. http://shareddecisions.mayoclinic.org/ . Accessed August 30, 2017.  
41. Stacey D, Légaré F, Lewis K, et al. Decision aids to help people who are facing health treatment 
or screening  decisions. Cochrane Database of Systematic Reviews. 2017  
42. Thomas V, Williams P, Sheridan S, Donahue K, Brenner A, McCormack L. Listening to the Field: 
Current State of the Science in Two Priority Areas - Shared Decision Making and Practice 
Improvement ( PI) in Ambulatory Settings. Research Triangle Park, NC: Final SDM Key Informant 
Interview Report. Prepared for the Agency for Healthcare Research & Quality; August 2016. 
Deliverable 1.5.2 Final SDM Summative Report.  
43. Agency for Healthcare Research and Q uality. The SHARE Approach. 
http://www.ahrq.gov/professionals/education/curriculum -
tools/shareddecisionmaking/index.html . Published 2017. Accessed January 24, 2017.  
44. McCormack L, Poehlman J, Boudewyns V, et al. Improvements and upgrades to AHRQ's 
Electronic Preventive Services Selector (ePSS). Rockville, MD: Final Report. Prepared by [CONTACT_468165], under Contr act No. HHSA2902009000211, for the Agency for Healthcare Research 
& Quality; September 2012.  
45. Monticone M, Ambrosini E, Cedraschi C, et al. Cognitive -behavioral Treatment for Subacute and 
Chronic Neck Pain: A Cochrane Review. Spi[INVESTIGATOR_050] (Phila Pa 1976). 2015 ;40(19):1495 -1504. 
doi:10.1097/BRS.[ADDRESS_599703] ed: Guilford Press; 2012.  
47. Armstrong MJ, Mottershead TA, Ronksley PE, Sigal RJ, Campbell TS, Hemmelgarn BR. 
Motivational interviewing to impro ve weight loss in overweight and/or obese patients: a 
systematic review and meta -analysis of randomized controlled trials. Obes Rev. 2011;12(9):709 -
723. doi:10.1111/j.1467 -789X.2011.[ZIP_CODE].x  
48. Ekong G, Kavookjian J. Motivational interviewing and outcomes in adults with type 2 diabetes: A 
systematic review. Patient Educ Couns. 2016;99(6):944 -952. doi:10.1016/j.pec.2015.11.022  
49. Elwyn G, Dehlendorf C, Epstein RM, Marrin K, White J, Frosch DL. Sh ared decision making and 
motivational interviewing: achieving patient -centered care across the spectrum of health care 
problems. Ann Fam Med. 2014;12(3):270 -275. doi:10.1370/afm.1615  
50. Otis JD. Managing chronic pain: a cognitive -behavioral therapy approa ch. Therapi[INVESTIGATOR_120540].  New 
York, NY: Oxford University Press; 2007.  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
References  
Page 79 of 81 51. Brasure M, MacDonald R, Fuchs E, et al. Management of Insomnia Disorder [Internet]. Rockville, 
MD: AHRQ Comparative Effectiveness Review; December 2015. Report No.: 15(16) -EHC027 -EF. 
52. Kendall PC, Peterman JS. CBT for Adolescents With Anxiety: Mature Yet Still Developi[INVESTIGATOR_007]. Am J 
Psychiatry. 2015;172(6):519 -530. doi:10.1176/appi.ajp.2015.14081061  
53. Beck AT. Cognitive therapy and the emotional disorders.  [LOCATION_001], NY:  Meridian; 1976.  
54. Kerns RD, Burns JW, Shulman M, et al. Can we improve cognitive -behavioral therapy for chronic 
back pain treatment engagement and adherence? A controlled trial of tailored versus standard 
therapy. Health psychology : official journal o f the Division of Health Psychology, American 
Psychological Association. 2014;33(9):938 -947. doi:10.1037/a0034406  
55. Butler AC, Chapman JE, Forman EM, Beck AT. The empi[INVESTIGATOR_468085] -behavioral 
therapy: a review of meta -analyses. Clin Psychol R ev. 2006;26(1):17 -31. 
doi:10.1016/j.cpr.2005.07.003  
56. Morley S, Eccleston C, Williams A. Systematic review and meta -analysis of randomized 
controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, 
excluding headac he. Pain. 1999;80(1 -2):1-13. doi:10.1016/s0304 -3959(98)[ADDRESS_599704]. Meta -analysis of psychological interventions for 
chronic low back pain. Health psychology : official journal of the Division of Health Psycholog y, 
American Psychological Association. 2007;26(1):1 -9. doi:10.1037/0278 -6133.26.1.1  
58. Eccleston C, Morley SJ, Williams AC. Psychological approaches to chronic pain management: 
evidence and challenges. Br J Anaesth. 2013;111(1):59 -63. doi:10.1093/bja/aet2 07 
59. Richmond H, Hall AM, Copsey B, et al. The Effectiveness of Cognitive Behavioural Treatment for 
Non -Specific Low Back Pain: A Systematic Review and Meta -Analysis. PLoS One. 
2015;10(8):e0134192. doi:10.1371/journal.pone.0134192  
60. Lamb SE, Mistry D, Lall R, et al. Group cognitive behavioural interventions for low back pain in 
primary care: extended follow -up of the Back Skills Training Trial (ISRCTN54717854). Pain. 
2012;153(2):494 -501. doi:10.1016/j.pain.2011.11.016  
61. Hansen Z, Daykin A, Lamb SE. A cognitive -behavioural programme for the management of low 
back pain in primary care: a description and justification of the intervention used in the Back 
Skills Training Trial (BeST; ISRCTN 54717854). Physiotherapy. 2010;96(2):87 -94. 
doi:10.1016/j.physio.2 009.09.008  
62. Thorn BE, Kuhajda MC. Group cognitive therapy for chronic pain. J Clin Psychol. 
2006;62(11):1355 -1366. doi:10.1002/jclp.[ZIP_CODE]  
63. Harden P, Ahmed S, Ang K, Wiedemer N. Clinical Implications of Tapering Chronic Opi[INVESTIGATOR_27262] a 
Veteran Population . Pain Med. 2015;16(10):1975 -1981. doi:10.1111/pme.[ZIP_CODE]  
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
References  
Page 80 of 81 64. Sullivan MD, Turner JA, DiLodovico C, D'Appollonio A, Stephens K, Chan YF. Prescription Opi[INVESTIGATOR_468086]: A Randomized Controlled Trial. The journal of 
pain : official journal of the American Pain Society. 2017;18(3):308 -318. 
doi:10.1016/j.jpain.2016.11.003  
65. Dillman DA, Smyth JD, Christian LM. Internet, phone, mail, and mixed -mode surveys: the tailored 
design method.  John Wiley & Sons; 2014.  
66. Dillman DA . Mail and Internet surveys: The tailored design method --2007 Update with new 
Internet, visual, and mixed -mode guide.  John Wiley & Sons; 2011.  
67. Centers for Disease Control and Prevention. 2018 BRFSS Data Collection Protocol with 
Disposition Table. https://www.health.ny.gov/funding/rfp/inactive/[ZIP_CODE]/attachment_e.pdf . 
Published 2018. Accessed 10/16/2019.  
68. Edlund MJ, Martin BC, Russo JE, DeVries A, Braden JB, Sullivan MD. The role of opi[INVESTIGATOR_468087]: the role of opi[INVESTIGATOR_16447]. Clin J Pain. 2014;30(7):557 -564. 
doi:10.1097/AJP.0000000000000021  
69. Edlund MJ, Austen MA, Sullivan MD, et al. Patterns of opi[INVESTIGATOR_468088] 2009 to 2011. Pain. 2014;155(11):2337 -2343. 
doi:10.1016/j.pain.2014.08.033  
70. Edlund MJ, Martin BC, Fan MY, Devries  A, Braden JB, Sullivan MD. Risks for opi[INVESTIGATOR_327541]: results from the TROUP study. Drug 
Alcohol Depend. 2010;112(1 -2):90 -98. doi:10.1016/j.drugalcdep.2010.05.017  
71. Edlund MJ, Martin BC, Fan MY, Bra den JB, Devries A, Sullivan MD. An analysis of heavy utilizers 
of opi[INVESTIGATOR_468089]. J Pain Symptom Manage. 
2010;40(2):279 -289. doi:10.1016/j.jpainsymman.2010.01.012  
72. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan  Braden J, Martin BC. Risks for possible and 
probable opi[INVESTIGATOR_416303]: The TROUP Study. Pain. 2010;150(2):332 -339. doi:10.1016/j.pain.2010.05.020  
73. Dworkin RH, Turk DC, F arrar JT, et al. Core outcome measures for chronic pain clinical trials: 
IMMPACT recommendations. Pain. 2005;113(1 -2):9-19. doi:10.1016/j.pain.2004.09.012  
74. Amtmann D, Cook KF, Jensen MP, et al. Development of a PROMIS item bank to measure pain 
interfere nce. Pain. 2010;150(1):173 -182. doi:10.1016/j.pain.2010.04.025  
75. Jensen RE, Potosky AL, Reeve BB, et al. Validation of the PROMIS physical function measures in a 
diverse US population -based cohort of cancer patients. Qual Life Res. 2015;24(10):2333 -2344.  
doi:10.1007/s11136 -015-0992 -9 
Integrated Health Services to Reduce Opi[INVESTIGATOR_467883]: The INSPI[INVESTIGATOR_467884]  
(IRB Number: 18 -0703 ) 
Study Protocol, v16, 03/30/2022  
 
References  
Page 81 of 81 76. Tan G, Jensen MP, Thornby [CONTACT_163692], Shanti BF. Validation of the Brief Pain Inventory for chronic 
nonmalignant pain. The journal of pain : official journal of the American Pain Society. 
2004;5(2):133 -137. doi:10.1016/j.jpain.20 03.12.005  
77. NIDA CTN Common Data Elements. Instrument: PROMIS Pain Intensity - Short Form 3a v1.0. 
NIDA website. https://cde.drugabuse.gov/instrument/0a481bfb -a5e6 -3c84-e050 -
bb89ad43314d . Published 2012. Accessed August 1, 2018.  
78. Pi[INVESTIGATOR_5544], Choi SW, Reise SP, et al. Item banks for measuring emotional distress from the 
Patient -Reported Outcomes Measurement Information System (PROM IS(R)): depression, 
anxiety, and anger. Assessment. 2011;18(3):263 -283. doi:10.1177/1073191111411667  
79. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic 
comorbidity in longitudinal studies: development and validation. Journal of chronic diseases. 
1987;40(5):373 -383. doi:10.1016/0021 -9681(87)[ZIP_CODE] -8 
80. Hochberg Y. A Sharpe r Bonferroni Procedure for Multiple Tests of Significance. Biometrika. 
1988;75(4):800 -802. doi: 10.2307/[ADDRESS_599705] 
designs. Indian J Stat. 2000;62(Series B, Par t 1):134 -148.  
82. Liu GHF, Lu KF, Mogg R, Mallick M, Mehrotra DV. Should baseline be a covariate or dependent 
variable in analyses of change from baseline in clinical trials? Statistics in Medicine. 
2009;28(20):2509 -2530. doi:10.1002/sim.3639  
83. Coffman C J, Edelman D, Woolson RF. To condition or not condition? Analysing 'change' in 
longitudinal randomised controlled trials. BMJ Open. 2016;6(12):e013096. 
doi:10.1136/bmjopen -2016 -013096  
84. Liebschutz JM, Xuan Z, Shanahan CW, et al. Improving Adherence to Lo ng-term Opi[INVESTIGATOR_468090]: A Cluster -Randomized Clinical Trial. JAMA 
Intern Med. 2017;177(9):1265 -1272. doi:10.1001/jamainternmed.2017.[ADDRESS_599706], Karlin BE.  Cognitive Behavioral Therapy 
for Chronic Pain Among Veterans:  Therapi[INVESTIGATOR_88388].  Washington, DC: U.S. Department of 
Veteran’s Affairs; n.d.  
86. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture 
(REDCap) --a metadata -driven methodology and workflow process for providing translational 
research informatics support. J Biomed Inform. 2009;42(2):377 -381. 
doi:10.1016/j.jbi.2008.08.010  
 